Breaking News

Friday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Earnings	Mersana Therapeutics reports Q2 EPS (33c), consensus (30c) » 06:06 08/07/20 08/07 06:06 08/07/20 06:06 MRSN Mersana Therapeutics $20.44 / -0.37 (-1.78%) Reports Q2 collaboration… Reports Q2 collaboration revenue $800,000, consensus $300,000. "Mersana is in a strong position to deliver on our vision of significantly advancing the ADC field for the benefit of patients in need. In just the first half of 2020, we have demonstrated strong proof of concept with XMT-1536 in ovarian cancer patients who have few options, initiated patient enrollment in the Phase 1 dose escalation study for XMT-1592, progressed our earlier programs into late-stage discovery and strengthened our balance sheet. We are working to rapidly advance XMT-1536 into registration-enabling studies and look forward to presenting a more comprehensive data disclosure around the end of the year as well as providing an incremental interim update on the ovarian cancer patient data at ESMO," said Anna Protopapas, President and CEO of Mersana Therapeutics. "Additionally, we look forward to disclosing our B7-H4 DolaLock candidate and first STING-agonist ADC candidate from our Immunosynthen platform in the second half of the year." ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options MRSN Mersana Therapeutics $20.44 / -0.37 (-1.78%) 06/22/20 Mersana Therapeutics presents preclinical data on XMT-1592 05/27/20 Mersana Therapeutics reports interim Phase 1 data for XMT-1536 cancer candidate 05/14/20 Mersana Therapeutics initiates patient dosing in XMT-1592 dose escalation study 05/13/20 Mersana Therapeutics to report interim data from Phase 1 dose expansion of XMT-1 MRSN Mersana Therapeutics $20.44 / -0.37 (-1.78%) 06/24/20 BTIG Mersana Therapeutics price target raised to $32 from $21 at BTIG 05/27/20 H.C. Wainwright Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright 04/29/20 BTIG Mersana Therapeutics initiated with a Buy at BTIG 01/21/20 H.C. Wainwright Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright MRSN Mersana Therapeutics $20.44 / -0.37 (-1.78%) 05/08/20 Mersana Therapeutics reports Q1 EPS (35c), consensus (37c) 02/28/20 Mersana Therapeutics reports Q4 EPS (34c), consensus (38c) 29 May MRSN Mersana Therapeutics $20.44 / -0.37 (-1.78%) 05/27/20 Fly Intel: Wall Street's top stories for Wednesday 04/13/20 Fly Insider: Carnival, SBA among week's notable insider transactions 08/11/20 Wedbush Pacgrow Healthcare Virtual Conference 08/07/20 Mersana Therapeutics - MRSN MRSN Mersana Therapeutics $20.44 / -0.37 (-1.78%) 02/12/20 Four new option listings and one option delisting on February 12th

Over a month ago
Conference/Events	Mersana Therapeutics participates in a conference call with BTIG » 09:25 06/25/20 06/25 09:25 06/25/20 09:25 MRSN Mersana Therapeutics $21.33 / +0.02 (+0.09%) Biotech Analyst Shrader… Biotech Analyst Shrader holds a conference call with management who discusses the Company's ADC platforms and programs on June 25 at 10 am hosted by BTIG. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options MRSN Mersana Therapeutics $21.33 / +0.02 (+0.09%) 06/22/20 Mersana Therapeutics presents preclinical data on XMT-1592 05/27/20 Mersana Therapeutics reports interim Phase 1 data for XMT-1536 cancer candidate 05/14/20 Mersana Therapeutics initiates patient dosing in XMT-1592 dose escalation study 05/13/20 Mersana Therapeutics to report interim data from Phase 1 dose expansion of XMT-1 MRSN Mersana Therapeutics $21.33 / +0.02 (+0.09%) 06/24/20 BTIG Mersana Therapeutics price target raised to $32 from $21 at BTIG 05/27/20 H.C. Wainwright Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright 04/29/20 BTIG Mersana Therapeutics initiated with a Buy at BTIG 01/21/20 H.C. Wainwright Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright MRSN Mersana Therapeutics $21.33 / +0.02 (+0.09%) 05/08/20 Mersana Therapeutics reports Q1 EPS (35c), consensus (37c) 02/28/20 Mersana Therapeutics reports Q4 EPS (34c), consensus (38c) MRSN Mersana Therapeutics $21.33 / +0.02 (+0.09%) 05/27/20 Fly Intel: Wall Street's top stories for Wednesday 04/13/20 Fly Insider: Carnival, SBA among week's notable insider transactions 06/25/20 Mersana Therapeutics - MRSN MRSN Mersana Therapeutics $21.33 / +0.02 (+0.09%) 02/12/20 Four new option listings and one option delisting on February 12th
Conference/Events	Mersana Therapeutics participates in a conference call with BTIG » 04:55 06/25/20 06/25 04:55 06/25/20 04:55 MRSN Mersana Therapeutics $21.33 / +0.02 (+0.09%) Biotech Analyst Shrader… Biotech Analyst Shrader holds a conference call with management who discusses the Company's ADC platforms and programs on June 25 at 10 am hosted by BTIG. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options MRSN Mersana Therapeutics $21.33 / +0.02 (+0.09%) 06/22/20 Mersana Therapeutics presents preclinical data on XMT-1592 05/27/20 Mersana Therapeutics reports interim Phase 1 data for XMT-1536 cancer candidate 05/14/20 Mersana Therapeutics initiates patient dosing in XMT-1592 dose escalation study 05/13/20 Mersana Therapeutics to report interim data from Phase 1 dose expansion of XMT-1 MRSN Mersana Therapeutics $21.33 / +0.02 (+0.09%) 06/24/20 BTIG Mersana Therapeutics price target raised to $32 from $21 at BTIG 05/27/20 H.C. Wainwright Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright 04/29/20 BTIG Mersana Therapeutics initiated with a Buy at BTIG 01/21/20 H.C. Wainwright Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright MRSN Mersana Therapeutics $21.33 / +0.02 (+0.09%) 05/08/20 Mersana Therapeutics reports Q1 EPS (35c), consensus (37c) 02/28/20 Mersana Therapeutics reports Q4 EPS (34c), consensus (38c) MRSN Mersana Therapeutics $21.33 / +0.02 (+0.09%) 05/27/20 Fly Intel: Wall Street's top stories for Wednesday 04/13/20 Fly Insider: Carnival, SBA among week's notable insider transactions 06/25/20 Mersana Therapeutics - MRSN MRSN Mersana Therapeutics $21.33 / +0.02 (+0.09%) 02/12/20 Four new option listings and one option delisting on February 12th
Recommendations	Mersana Therapeutics price target raised to $32 from $21 at BTIG » 06:56 06/24/20 06/24 06:56 06/24/20 06:56 MRSN Mersana Therapeutics $21.31 / -0.16 (-0.75%) BTIG analyst Thomas… BTIG analyst Thomas Shrader raised the firm's price target on Mersana Therapeutics to $32 from $21 and keeps a Buy rating on the shares. The analyst says the company's "immunosynthen based STING-agonist ADC platform that employs mAbs conjugated with a novel STING agonist payload" that was presented yesterday looks "compelling". Shrader adds to his model the initial commercial opportunity for Mersana's platform in NSCLC indication, where immunotherapies are currently approved. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options MRSN Mersana Therapeutics $21.31 / -0.16 (-0.75%) 06/22/20 Mersana Therapeutics presents preclinical data on XMT-1592 05/27/20 Mersana Therapeutics reports interim Phase 1 data for XMT-1536 cancer candidate 05/14/20 Mersana Therapeutics initiates patient dosing in XMT-1592 dose escalation study 05/13/20 Mersana Therapeutics to report interim data from Phase 1 dose expansion of XMT-1 MRSN Mersana Therapeutics $21.31 / -0.16 (-0.75%) 05/27/20 H.C. Wainwright Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright 04/29/20 BTIG Mersana Therapeutics initiated with a Buy at BTIG 01/21/20 H.C. Wainwright Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright 08/20/19 H.C. Wainwright H.C. Wainwright says trial initiation at higher dosing 'bodes well' for Mersana MRSN Mersana Therapeutics $21.31 / -0.16 (-0.75%) 05/08/20 Mersana Therapeutics reports Q1 EPS (35c), consensus (37c) 02/28/20 Mersana Therapeutics reports Q4 EPS (34c), consensus (38c) MRSN Mersana Therapeutics $21.31 / -0.16 (-0.75%) 05/27/20 Fly Intel: Wall Street's top stories for Wednesday 04/13/20 Fly Insider: Carnival, SBA among week's notable insider transactions 06/25/20 Mersana Therapeutics - MRSN MRSN Mersana Therapeutics $21.31 / -0.16 (-0.75%) 02/12/20 Four new option listings and one option delisting on February 12th
Conference/Events	Mersana Therapeutics participates in a conference call with BTIG » 15:37 06/22/20 06/22 15:37 06/22/20 15:37 MRSN Mersana Therapeutics $21.14 / +0.88 (+4.34%) Biotech Analyst Shrader… Biotech Analyst Shrader holds a conference call with management who discusses the Company's ADC platforms and programs on June 25 at 10 am hosted by BTIG. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options MRSN Mersana Therapeutics $21.14 / +0.88 (+4.34%) 06/22/20 Mersana Therapeutics presents preclinical data on XMT-1592 05/27/20 Mersana Therapeutics reports interim Phase 1 data for XMT-1536 cancer candidate 05/14/20 Mersana Therapeutics initiates patient dosing in XMT-1592 dose escalation study 05/13/20 Mersana Therapeutics to report interim data from Phase 1 dose expansion of XMT-1 MRSN Mersana Therapeutics $21.14 / +0.88 (+4.34%) 05/27/20 H.C. Wainwright Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright 04/29/20 BTIG Mersana Therapeutics initiated with a Buy at BTIG 01/21/20 H.C. Wainwright Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright 08/20/19 H.C. Wainwright H.C. Wainwright says trial initiation at higher dosing 'bodes well' for Mersana MRSN Mersana Therapeutics $21.14 / +0.88 (+4.34%) 05/08/20 Mersana Therapeutics reports Q1 EPS (35c), consensus (37c) 02/28/20 Mersana Therapeutics reports Q4 EPS (34c), consensus (38c) MRSN Mersana Therapeutics $21.14 / +0.88 (+4.34%) 05/27/20 Fly Intel: Wall Street's top stories for Wednesday 04/13/20 Fly Insider: Carnival, SBA among week's notable insider transactions MRSN Mersana Therapeutics $21.14 / +0.88 (+4.34%) 02/12/20 Four new option listings and one option delisting on February 12th

Hot Stocks	Mersana Therapeutics presents preclinical data on XMT-1592 » 09:30 06/22/20 06/22 09:30 06/22/20 09:30 MRSN Mersana Therapeutics $20.26 / -0.69 (-3.29%) Mersana Therapeutics… Mersana Therapeutics presented preclinical data for XMT-1592, its clinical stage Dolasynthen ADC targeting NaPi2b, as well as progress on its Immunosynthen STING-agonist ADC platform at the American Association for Cancer Research 2020 Virtual Annual Meeting. Poster Title: XMT-1592, a Site-Specific Dolasynthen-Based NaPi2b-Targeted Antibody-Drug Conjugate for the Treatment of Ovarian Cancer and Lung Adenocarcinoma: XMT-1592 is an ADC created using Dolasynthen, Mersana's proprietary, customizable and homogeneous platform designed to precisely optimize an ADC for a given target, drug-to-antibody ratio and antibody. XMT-1592 is currently in an ongoing Phase 1 dose escalation study to determine the maximum tolerated dose in patients with non-small cell lung cancer adenocarcinoma and ovarian cancer. This poster evaluates the benefits of site-specific bioconjugation of Dolasynthen by reporting in vitro and in vivo comparisons of XMT-1592 to a stochastically conjugated version of the ADC. XMT-1592 shows improved in vivo activity, pharmacokinetics and clinical pathology relative to its stochastic counterpart. These data also show that XMT-1592 induced sustained tumor regressions in an NSCLC adenocarcinoma patient-derived xenograft. Poster Title: Systemic Administration of STING-Agonist Antibody-Drug Conjugates Elicit Potent Anti-Tumor Immune Responses with Minimal Induction of Circulating Cytokines These data presented today show that Immunosynthen represents a novel STING-agonist ADC platform for the systemic administration of a therapeutic agent with targeted immune-stimulatory effects. These data show target-dependent anti-tumor immune responses in vitro and in vivo as a single well-tolerated dose for multiple targets in multiple preclinical models. The data also show that the STING-agonist ADC was more active with limited induction of systemic cytokines when compared to intravenously administered unconjugated agonist, suggesting it may confer an improved therapeutic index. In addition, potent ADC-mediated tumor regression led to durable immunological memory in an immune competent model. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options MRSN Mersana Therapeutics $20.26 / -0.69 (-3.29%) 05/27/20 Mersana Therapeutics reports interim Phase 1 data for XMT-1536 cancer candidate 05/14/20 Mersana Therapeutics initiates patient dosing in XMT-1592 dose escalation study 05/13/20 Mersana Therapeutics to report interim data from Phase 1 dose expansion of XMT-1 04/15/20 Mersana Therapeutics appoints Martin Huber to board of directors MRSN Mersana Therapeutics $20.26 / -0.69 (-3.29%) 05/27/20 H.C. Wainwright Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright 04/29/20 BTIG Mersana Therapeutics initiated with a Buy at BTIG 01/21/20 H.C. Wainwright Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright 08/20/19 H.C. Wainwright H.C. Wainwright says trial initiation at higher dosing 'bodes well' for Mersana MRSN Mersana Therapeutics $20.26 / -0.69 (-3.29%) 05/08/20 Mersana Therapeutics reports Q1 EPS (35c), consensus (37c) 02/28/20 Mersana Therapeutics reports Q4 EPS (34c), consensus (38c) MRSN Mersana Therapeutics $20.26 / -0.69 (-3.29%) 05/27/20 Fly Intel: Wall Street's top stories for Wednesday 04/13/20 Fly Insider: Carnival, SBA among week's notable insider transactions MRSN Mersana Therapeutics $20.26 / -0.69 (-3.29%) 02/12/20 Four new option listings and one option delisting on February 12th
Conference/Events	American Society of Clinical Oncology (ASCO) to hold virtual meeting » 04:55 05/31/20 05/31 04:55 05/31/20 04:55 ABBV AbbVie $92.78 / +2.77 (+3.08%) , ALLO Allogene Therapeutics $48.08 / +1.48 (+3.18%) , AMGN Amgen $230.13 / +6.11 (+2.73%) , ATNX Athenex $10.91 / -0.21 (-1.89%) , AVEO Aveo Pharmaceuticals $8.14 / -1.08 (-11.71%) , AZN AstraZeneca $54.60 / +1.1 (+2.06%) , BCYC Bicycle Therapeutics $17.50 / -0.785 (-4.29%) , BLUE Bluebird Bio $63.63 / +2.82 (+4.64%) , BPMC Blueprint Medicines $65.16 / -1.84 (-2.75%) , CGEN Compugen $15.50 / +3.13 (+25.30%) , HALO Halozyme $24.26 / +0.79 (+3.37%) , EXEL Exelixis $24.68 / +0.35 (+1.44%) , DCPH Deciphera $58.47 / +1.53 (+2.69%) , KURA Kura Oncology $17.09 / +0.38 (+2.27%) , KPTI Karyopharm $18.49 / -0.31 (-1.65%) , MRK Merck $80.85 / +1.83 (+2.32%) , BMY Bristol-Myers $59.72 / -0.08 (-0.13%) , MRSN Mersana Therapeutics $22.55 / +2.85 (+14.47%) , NXTC NextCure $31.20 / -1.96 (-5.91%) , PFE Pfizer $38.14 / -0.03 (-0.08%) , RECN Changed to RGP $0.00 / + (+0.00%) , REPL Replimune Group $18.85 / +0.3 (+1.62%) , SBPH Spring Bank Pharmaceuticals $1.66 / +0.015 (+0.91%) , SGEN Seattle Genetics $157.30 / +5.53 (+3.64%) , STML Stemline $11.89 / + (+0.00%) , SYRS Syros Pharmaceuticals $9.77 / +0.25 (+2.63%) , TRIL Trillium Therapeutics $6.76 / +0.995 (+17.26%) , TROV Changed name to CRDF $0.00 / + (+0.00%) , XNCR Xencor $30.30 / -0.69 (-2.23%) Virtual Annual Meeting of… Virtual Annual Meeting of ASCO 2020 will be held on May 29-31. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options XNCR TROV TRIL SYRS STML SGEN SBPH REPL RECN PFE NXTC MRSN MRK KURA KPTI HALO EXEL DCPH CGEN BPMC BMY BLUE BCYC AZN AVEO ATNX AMGN ALLO ABBV XNCR Xencor $30.30 / -0.69 (-2.23%) 05/13/20 Xencor reports initial dose escalation in ph1 study of XmAb20717 03/25/20 Xencor, Vir Biotechnology enter license agreement for use of Xtend in Covid-19 03/24/20 Exagen appoints Debra Jeske Zack as CMO, Anja Kammesheidt as CSO 02/05/20 Aimmune obtains license for XmAb7195 from Xencor for $5M in cash, $5M in equity TROV Changed name to CRDF $0.00 / + (+0.00%) 05/06/20 Trovagene changing company name to Cardiff Oncology, appoints Mark Erlander CEO 04/28/20 Trovagene announces results from Phase 1b/2 clinical trial of onvansertib 02/13/20 Trovagene presents Phase 2 efficacy data on onvansertib for mCRPC 01/29/20 Trovagene receives approximately $1.45M from exercise of warrants TRIL Trillium Therapeutics $6.76 / +0.995 (+17.26%) 05/29/20 Trillium updates dose escalation sudy of CD47 Blocker TTI-622 at ASCO 05/06/20 Trillium Therapeutics announces ATM equity program 04/08/20 Trillium Therapeutics says difficult to predict COVID-19 impact 04/08/20 Trillium Therapeutics says cash runway 'sufficient' into 2022 SYRS Syros Pharmaceuticals $9.77 / +0.25 (+2.63%) 05/29/20 Syros Pharmaceuticals presents new preclinical data for SY-5609 at ASCO 04/02/20 Point72 discloses 5.1% passive stake in Syros Pharmaceuticals 01/29/20 Syros Pharmaceuticals announces preclinical data on CDK7, CDK12 01/28/20 Syros Pharmaceuticals doses first patient in SY-5609 Phase 1 clinical trial STML Stemline $11.89 / + (+0.00%) 05/04/20 Stemline trading resumes 05/04/20 Menarini Group to acquire Stemline in transaction valued at up to $677M 05/04/20 Stemline trading halted, news pending 01/13/20 Fly Intel: After Hours Movers SGEN Seattle Genetics $157.30 / +5.53 (+3.64%) 05/29/20 Seattle Genetics announces results from exploratory analyses of HER2CLIMB trial 05/14/20 Takeda Pharmaceutical receives EC approval for Adcetris MA extension 05/12/20 Seattle Genetics Tukysa receives Swiss Agency for Therapeutic Products approval 04/30/20 Seattle Genetics sees FY20 ADCETRIS net product sales $675M-$700M SBPH Spring Bank Pharmaceuticals $1.66 / +0.015 (+0.91%) 04/02/20 Spring Bank Pharmaceuticals continues trial for IB SB 11285 04/02/20 Spring Bank says safety committee for SB 11285 trial recommends dose escalation 02/25/20 Spring Bank, Roche announces collaboration to evaluate SB 11285 w/ atezolizumab 01/29/20 Spring Bank down 4.5% after discontinuing development of inarigivir soproxil REPL Replimune Group $18.85 / +0.3 (+1.62%) 04/02/20 Replimune Group appoints Dieter Weinand as chairman of the board 02/13/20 Replimune Group 'on track' to initiate Phase 1 trial of RP3 in 2020 02/13/20 Replimune Group expects inital data from Phase 1 trial of RP2 by end of 2020 02/13/20 Replimune Group 'on track' to initiate Phase 1/2 trial of RP1 in 1H20 RECN Changed to RGP $0.00 / + (+0.00%) 03/30/20 Resources Connection to change trading symbol to 'RGP' 02/04/20 Resources Connection names Jennifer Ryu as new CFO 01/03/20 Resources Connections rises after upbeat Q2 earnings 01/02/20 Fly Intel: After Hours Movers PFE Pfizer $38.14 / -0.03 (-0.08%) 05/29/20 Pfizer shares down 8.4% following Phase 3 PALLAS Ibrance trial update 05/29/20 Pfizer reports Phase 3 PALLAS Ibrance trial unlikely to meet endpoint 05/29/20 Pfizer, Astellas Pharma: PROSPER results show XTANDI 'signifcantly extends' OS 05/28/20 Corning, Pfizer announce supply agreement for Corning Valor Glass Packaging NXTC NextCure $31.20 / -1.96 (-5.91%) 05/29/20 NextCure presents biomarker data, results form NC318 trial at ASCO 04/13/20 NextCure temporarily delays start of NC410 Phase 1/2 trial 04/13/20 NextCure expects data from Phase 2 of Phase 1/2 NC318 trial to be delayed 04/13/20 NextCure temporarily delays start of NC318 combination clinical trial MRSN Mersana Therapeutics $22.55 / +2.85 (+14.47%) 05/27/20 Mersana Therapeutics reports interim Phase 1 data for XMT-1536 cancer candidate 05/14/20 Mersana Therapeutics initiates patient dosing in XMT-1592 dose escalation study 05/13/20 Mersana Therapeutics to report interim data from Phase 1 dose expansion of XMT-1 04/15/20 Mersana Therapeutics appoints Martin Huber to board of directors MRK Merck $80.85 / +1.83 (+2.32%) 05/28/20 Merck, Eisai announce new data from KEYTRUDA plus LENVIMA trials 05/28/20 Merck study shows KEYTRUDA reduced risk of progression, death by 40% 05/26/20 Merck jumps 2.5% in premarket trading on plans for COVID-19 vaccines, treatment 05/26/20 Merck, Ridgeback Bio collaborate to advance development of EIDD-2801 KURA Kura Oncology $17.09 / +0.38 (+2.27%) 05/29/20 Kura reports data from tipifarnib study of metastatic HRAS mutant HNSCC 03/03/20 Kura Oncology receives Fast Track designation for tipifarnib in T-cell lymphomas 01/23/20 Kura Oncology appoints Bridget Martell acting Chief Medical Officer 01/06/20 Kura Oncology appoints Kirsten Flowers as CCO KPTI Karyopharm $18.49 / -0.31 (-1.65%) 05/28/20 Karyopharm reports Phase 3 Boston data in ASCO presentation 05/20/20 Karyopharm submits sNDA to FDA for XPOVIO 05/13/20 Karyopharm donates 60,000 medical masks across Massachusetts, the U.S. 05/05/20 Antengene broadens partnership with Karyopharm HALO Halozyme $24.26 / +0.79 (+3.37%) 05/14/20 Halozyme to receive $15M milestone payment from Johnson & Johnson's Janssen 05/01/20 Halozyme announces FDA approval of DARZALEX FASPRO for Janssen Biotech 04/30/20 Halozyme discloses Janssen receipt CHMP positive opinion for Darzalex 04/27/20 Halozyme announces daratumumab NDA filed in Japan by Janssen EXEL Exelixis $24.68 / +0.35 (+1.44%) 05/13/20 Exelixis to present ph. 1b trial results for cabozantinib+atezolizumab as ASCO 04/20/20 Bristol-Myers, Exelixis: CheckMate-9ER met primary endpoint of PFS 03/25/20 Exelixis says Takeda Pharmaceutical receives approval in Japan for CABOMETYX 02/25/20 Fly Intel: After Hours Movers DCPH Deciphera $58.47 / +1.53 (+2.69%) 05/29/20 Deciphera presents results from INVICTUS pivotal Phase 3 study at ASCO 05/29/20 Deciphera presents data from cohort of Part 2 of rebastinib Phase 1b/2 at ASCO 05/15/20 Deciphera announces FDA approval of QINLOCK for treatment of GIST 05/15/20 Deciphera up over 5% after receiving FDA approval for ripretinib in 4L+GIST CGEN Compugen $15.50 / +3.13 (+25.30%) 05/27/20 Compugen doses first patient in COM701 Phase 1 monotherapy expansion cohort 04/22/20 Compugen granted patent in Europe for backup cancer antibodies 04/20/20 Compugen and Bayer's BAY 1905254 study results published in reviewed paper 04/06/20 Compugen: First patient dosed in COM902 Phase 1 trial BPMC Blueprint Medicines $65.16 / -1.84 (-2.75%) 05/29/20 Blueprint Medicines presents data from ARROW clinical trial of pralsetinib 05/15/20 Blueprint Medicines receives CRL from FDA on NDA for avapritinib 05/06/20 Blueprint Medicines: Cash sufficient to fund operating expenses to 2H22 04/28/20 Blueprint Medicines trading resumes BMY Bristol-Myers $59.72 / -0.08 (-0.13%) 05/29/20 Heat Biologics presents HS-110/Opdivo combination Phase 2 trial data at ASCO 05/28/20 WindMIL doses first patient in Phase 2 study of MILs in combo w/ nivolumab 05/27/20 TCR2 Therapeutics appoints Gregg McConnell as head of business development BLUE Bluebird Bio $63.63 / +2.82 (+4.64%) 05/29/20 Bristol-Myers CEO says 'very much on track' with ide-cel resubmission 05/13/20 Bluebird Bio, Bristol-Myers to update results from KarMMa Study of Ide-cel 05/13/20 Bluebird sinks after FDA issues Refusal to File letter for myeloma treatment 05/13/20 Bristol-Myers, Bluebird Bio receive RTF letter on BLA for idecabtagene vicleucel BCYC Bicycle Therapeutics $17.50 / -0.785 (-4.29%) 05/05/20 Bicycle announces dosing of first patient in Phase I study of BT5528 04/07/20 Bicycle Therapeutics expects to reach 2020 milestones as planned 03/12/20 Bicycle Therapeutics PLC (ADS) trading resumes 03/12/20 Bicycle Therapeutics PLC (ADS) trading halted, volatility trading pause AZN AstraZeneca $54.60 / +1.1 (+2.06%) 05/29/20 AstraZeneca reports results from updated CASPIAN trial analysis 05/29/20 AstraZeneca says Imfinzi showed sustained overall survival benefit 05/29/20 AstraZeneca announces results from Imfinzi plus tremelimumab trial 05/29/20 AstraZeneca says Enhertu improved overall survival in gastric cancer trial AVEO Aveo Pharmaceuticals $8.14 / -1.08 (-11.71%) 05/29/20 Aveo Pharmaceuticals DEDUCTIVE trial advances to Phase 2 portion 05/29/20 Aveo presents results from final analysis of Phase 3 TIVO-3 trial 03/31/20 Aveo submits NDA to FDA for tivozanib 03/27/20 Aveo Oncology discontinues CyFi-2 study due to impact of COVID-19 ATNX Athenex $10.91 / -0.21 (-1.89%) 05/29/20 Athenex presents interim data from oral paclitaxel Phase II study 05/07/20 Athenex sees 2020 y-o-y product sales growth in mid-single digits 05/07/20 Athenex announces upcoming milestones 05/07/20 Athenex expects cash, cash equivalents to fund operations into 1Q21 AMGN Amgen $230.13 / +6.11 (+2.73%) 05/29/20 Amgen presents new AMG 510 clinical data 05/08/20 Cytokinetics, Amgen granted Fast Track designation for omecamtiv mecarbil 05/08/20 Amgen,Cytokinetics: FDA grants Fast Track designation for omecamtiv mecarbil 05/06/20 Amgen reports 'positive' results from Otezla Phase 3 ADVANCE study ALLO Allogene Therapeutics $48.08 / +1.48 (+3.18%) 05/29/20 Allogene Therapeutics reports results from Phase 1 ALPHA study of ALLO-501 05/26/20 Allogene Therapeutics announces webinar to review initial ALLO-501 phase 1 data 05/13/20 Allogene Therapeutics jumps 32% after reporting ALLO-501 data 05/06/20 Allogene Therapeutics expects 2020 net losses $260M-$280M ABBV AbbVie $92.78 / +2.77 (+3.08%) 05/29/20 FDA announces approval of AbbVie's Oriahnn 05/27/20 Ironwood, AbbVie announce MD-7246 trial did not meet primary endpoint 05/21/20 Synlogic announces termination of IBD treatment collaboration with AbbVie 05/12/20 AbbVie director sells 23K shares of common stock ABBV ALLO AMGN ATNX AVEO AZN BCYC BLUE BPMC CGEN HALO EXEL DCPH KURA KPTI MRK BMY MRSN NXTC PFE RECN REPL SBPH SGEN STML SYRS TRIL TROV XNCR ABBV AbbVie $92.78 / +2.77 (+3.08%) 05/22/20 Piper Sandler Growth of Biohaven's Nurtec continues to beat AbbVie's Ubrelvy, says Piper 05/21/20 Piper Sandler Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration 05/18/20 BofA AbbVie reinstated with a Neutral at BofA 05/12/20 JPMorgan AbbVie resumed with an Overweight from Neutral at JPMorgan ALLO Allogene Therapeutics $48.08 / +1.48 (+3.18%) 05/29/20 H.C. Wainwright Allogene Therapeutics price target raised to $55 from $42 at H.C. Wainwright 05/29/20 Piper Sandler Allogene Therapeutics price target raised to $70 from $50 at Piper Sandler 05/19/20 Roth Capital Allogene Therapeutics upgraded to Buy with $60 target at Roth Capital 05/19/20 Roth Capital Allogene Therapeutics upgraded to Buy from Neutral at Roth Capital AMGN Amgen $230.13 / +6.11 (+2.73%) 05/28/20 Piper Sandler Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler 05/28/20 Cowen Alexion settlement may yield upside surprise, says Cowen 05/28/20 Stifel Alexion, Amgen appear to have agreed to settlement deal, says Stifel 05/22/20 Piper Sandler Harpoon Therapeutics initiated with an Overweight at Piper Sandler ATNX Athenex $10.91 / -0.21 (-1.89%) 12/13/19 RBC Capital Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital 12/06/19 Truist Athenex initiated with a Buy at SunTrust 11/19/19 RBC Capital Athenex gets 'third SABCS win' ahead of meeting, says RBC Capital 08/07/19 RBC Capital Athenex's Oraxol data 'near best-case,' says RBC Capital AVEO Aveo Pharmaceuticals $8.14 / -1.08 (-11.71%) 05/29/20 Piper Sandler Aveo Pharmaceuticals price target raised to $26 from $18.50 at Piper Sandler 05/29/20 Baird Aveo Pharmaceuticals price target raised to $24 from $15 at Baird 05/01/20 H.C. Wainwright Aveo Pharmaceuticals price target raised to $10 from $6 at H.C. Wainwright 04/01/20 H.C. Wainwright Aveo Pharmaceuticals price target raised to $6 from $4 at H.C. Wainwright AZN AstraZeneca $54.60 / +1.1 (+2.06%) 05/29/20 Guggenheim AstraZeneca price target raised to 10,100 GBp from 9,100 GBp at Guggenheim 05/14/20 Evercore ISI Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine 05/06/20 Morgan Stanley AstraZeneca price target raised to 8,630 GBp from 8,600 GBp at Morgan Stanley 05/04/20 Citi Citi opens 'positive catalyst watch' on AstraZeneca BCYC Bicycle Therapeutics $17.50 / -0.785 (-4.29%) 04/17/20 Fly Intel: Top five analyst initiations 04/17/20 H.C. Wainwright Bicycle Therapeutics initiated with a Buy at H.C. Wainwright 04/07/20 Piper Sandler Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler 02/25/20 Piper Sandler Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler BLUE Bluebird Bio $63.63 / +2.82 (+4.64%) 05/13/20 Stifel Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel 05/13/20 Piper Sandler Bluebird should be able to easily address RTF issues, says Piper Sandler 05/12/20 RBC Capital Bluebird Bio initiated with an Outperform at RBC Capital 05/12/20 Oppenheimer Bluebird Bio price target lowered to $111 from $122 at Oppenheimer BPMC Blueprint Medicines $65.16 / -1.84 (-2.75%) 05/29/20 Raymond James Blueprint approval for pralsetinib could come before PDUFA, says Raymond James 05/06/20 Nomura Instinet Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet 05/05/20 Barclays Blueprint Medicines initiated with an Equal Weight at Barclays 04/29/20 SVB Leerink Deciphera price target raised to $55 from $50 at SVB Leerink CGEN Compugen $15.50 / +3.13 (+25.30%) 05/26/20 JMP Securities Compugen resumed with an Outperform at JMP Securities 05/13/20 Fly Intel: Top five analyst initiations 05/13/20 Stifel Compugen initiated with a Buy at Stifel 05/07/20 Fly Intel: Top five analyst initiations HALO Halozyme $24.26 / +0.79 (+3.37%) 05/26/20 Piper Sandler Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler 05/12/20 JMP Securities Halozyme price target raised to $34 from $24 at JMP Securities 05/04/20 Cantor Fitzgerald Halozyme price target raised to $39 from $35 at Cantor Fitzgerald 03/23/20 Citi Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak EXEL Exelixis $24.68 / +0.35 (+1.44%) 05/14/20 Truist Exelixis price target raised to $40 from $35 at SunTrust 05/13/20 Piper Sandler Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler 05/06/20 Piper Sandler Exelixis price target raised to $30 from $23 at Piper Sandler 04/21/20 Guggenheim Exelixis price target raised to $32 from $27 at Guggenheim DCPH Deciphera $58.47 / +1.53 (+2.69%) 05/18/20 Truist Deciphera price target raised to $91 from $82 at SunTrust 05/18/20 Barclays Deciphera price target raised to $85 from $80 at Barclays 05/18/20 Piper Sandler Piper Sandler a buyer of Deciphera shares on the open 05/15/20 Piper Sandler Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler KURA Kura Oncology $17.09 / +0.38 (+2.27%) 05/29/20 Piper Sandler Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler 05/29/20 H.C. Wainwright Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright 05/19/20 Deutsche Bank Kura Oncology price target lowered to $24 from $28 at Deutsche Bank 05/06/20 Wedbush Kura prioritizing development of tipifarnib for HRAS-HNSCC, says Wedbush KPTI Karyopharm $18.49 / -0.31 (-1.65%) 05/06/20 H.C. Wainwright Karyopharm price target lowered to $40 from $43 at H.C. Wainwright 04/07/20 Wedbush Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID 04/07/20 H.C. Wainwright XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright 03/04/20 Barclays Karyopharm initiated with an Overweight at Barclays MRK Merck $80.85 / +1.83 (+2.32%) 05/27/20 Alliance Global Partners PDS Biotechnology initiated with a Buy at Alliance Global Partners 05/20/20 JonesTrading Merck collaboration positions Surface Oncology well, says JonesTrading 04/27/20 SVB Leerink Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades 04/06/20 Raymond James NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James BMY Bristol-Myers $59.72 / -0.08 (-0.13%) 04/20/20 Piper Sandler Exelixis combo approval would increase kidney cancer use, says Piper Sandler MRSN Mersana Therapeutics $22.55 / +2.85 (+14.47%) 05/27/20 H.C. Wainwright Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright 04/29/20 BTIG Mersana Therapeutics initiated with a Buy at BTIG 01/21/20 H.C. Wainwright Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright 08/20/19 H.C. Wainwright H.C. Wainwright says trial initiation at higher dosing 'bodes well' for Mersana NXTC NextCure $31.20 / -1.96 (-5.91%) 05/29/20 Piper Sandler NextCure data shows S15-mediated activity, says Piper Sandler 05/26/20 JMP Securities NextCure initiated with an Outperform at JMP Securities 04/13/20 Piper Sandler NextCure could report Phase I biomarker data at ASCO, says Piper Sandler 03/24/20 Benchmark NextCure initiated with a Buy at Benchmark PFE Pfizer $38.14 / -0.03 (-0.08%) 05/21/20 Piper Sandler Gilead's filgotinib likely being underestimated by Street, says Piper Sandler 05/19/20 H.C. Wainwright BioNTech upgraded to Buy from Neutral at H.C. Wainwright 05/15/20 Goldman Sachs After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy 05/15/20 JPMorgan JPMorgan still sees Sarepta in pole position in DMD space RECN Changed to RGP $0.00 / + (+0.00%) 01/03/20 Baird Resources Connection Q3 guidance 'materially below' expectations, says Baird 10/03/19 JPMorgan Resources Connection near-term outlook remains challenged, says JPMorgan REPL Replimune Group $18.85 / +0.3 (+1.62%) 05/05/20 Barclays Replimune Group initiated with an Overweight at Barclays 03/25/20 Wedbush Replimune Group added to Best Ideas List at Wedbush 11/11/19 Roth Capital Replimune Group price target raised to $30 from $20 at Roth Capital 09/04/19 Roth Capital Replimune Group initiated with a Buy at Roth Capital SBPH Spring Bank Pharmaceuticals $1.66 / +0.015 (+0.91%) 04/02/20 Piper Sandler Piper Sandler keeps Neutral on Spring Bank as study enrollment expected to slow 01/29/20 Jefferies Spring Bank Pharmaceuticals downgraded to Hold from Buy at Jefferies 01/29/20 Piper Sandler Piper keeps Neutral rating on Spring Bank after inarigivir discontinued 12/30/19 Fly Intel: Top five analyst actions SGEN Seattle Genetics $157.30 / +5.53 (+3.64%) 05/26/20 Goldman Sachs Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs 05/26/20 JMP Securities Seattle Genetics initiated with an Outperform at JMP Securities 05/26/20 Goldman Sachs Incyte downgraded to Buy from Conviction Buy at Goldman Sachs 05/26/20 Goldman Sachs Seattle Genetics upgraded to Conviction Buy from Buy at Goldman Sachs STML Stemline $11.89 / + (+0.00%) 05/05/20 H.C. Wainwright Stemline downgraded to Neutral from Buy at H.C. Wainwright 05/05/20 Ladenburg Stemline downgraded to Neutral from Buy at Ladenburg 05/04/20 Alliance Global Partners Stemline downgraded to Neutral from Buy at Alliance Global Partners 05/04/20 Wedbush Stemline downgraded to Neutral from Outperform at Wedbush SYRS Syros Pharmaceuticals $9.77 / +0.25 (+2.63%) 05/29/20 Roth Capital Syros Pharmaceuticals ASCO update bodes well for ph1 data, says Roth Capital 05/29/20 Piper Sandler Syros price target raised to $14 after ASCO update at Piper Sandler 04/23/20 JonesTrading Syros Pharmaceuticals initiated with a Buy at JonesTrading 03/06/20 H.C. Wainwright Syros Pharmaceuticals price target lowered to $8 from $10 at H.C. Wainwright TRIL Trillium Therapeutics $6.76 / +0.995 (+17.26%) 05/26/20 JMP Securities Trillium Therapeutics initiated with an Outperform at JMP Securities 08/19/19 Fly Intel: Top five analyst downgrades 08/19/19 H.C. Wainwright Trillium Therapeutics downgraded to Neutral from Buy at H.C. Wainwright TROV Changed name to CRDF $0.00 / + (+0.00%) 01/28/20 Noble Capital Trovagene resumed with an Outperform at Noble Capital XNCR Xencor $30.30 / -0.69 (-2.23%) 05/13/20 Piper Sandler Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler 03/04/20 Barclays Barclays starts small, mid cap Biotechnology sector with Positive view 03/04/20 Barclays Xencor initiated with an Underweight at Barclays 02/25/20 Guggenheim Xencor upgraded to Buy from Neutral at Guggenheim XNCR TRIL SYRS STML SGEN SBPH REPL RECN PFE NXTC MRSN MRK KURA KPTI HALO EXEL DCPH CGEN BPMC BMY BLUE BCYC AZN AVEO ATNX AMGN ALLO ABBV XNCR Xencor $30.30 / -0.69 (-2.23%) 05/07/20 Xencor reports Q1 EPS (14c), consensus (38c) 02/24/20 Xencor sees ending 2020 with $500M-$550M in cash 02/24/20 Xencor reports Q4 EPS (47c), consensus (41c) TRIL Trillium Therapeutics $6.76 / +0.995 (+17.26%) 05/15/20 Trillium Therapeutics reports Q1 EPS ($1.07), consensus (90c) 03/10/20 Trillium Therapeutics reports FY19 EPS ($1.65) vs. ($2.35) last year SYRS Syros Pharmaceuticals $9.77 / +0.25 (+2.63%) 05/13/20 Syros Pharmaceuticals director Mark Alles bought 10K shares of company stock 05/07/20 Syros Pharmaceuticals reports Q1 EPS (39c), consensus (43c) 03/05/20 Syros Pharmaceuticals reports Q4 EPS (46c), consensus (47c) STML Stemline $11.89 / + (+0.00%) 03/13/20 Stemline Therapeutics reports Q4 EPS (38c), consensus (35c) SGEN Seattle Genetics $157.30 / +5.53 (+3.64%) 04/30/20 Seattle Genetics reports Q1 EPS (98c), consensus (79c) 02/06/20 Seattle Genetics sees 2020 Adcetris net sales $675M-$700M 02/06/20 Seattle Genetics reports Q4 EPS 14c, consensus (45c) 02/06/20 Notable companies reporting after market close SBPH Spring Bank Pharmaceuticals $1.66 / +0.015 (+0.91%) 02/14/20 Spring Bank Pharmaceuticals reports Q4 EPS (45c), consensus (67c) REPL Replimune Group $18.85 / +0.3 (+1.62%) 02/13/20 Replimune Group reports Q3 EPS (46c), consensus (36c) RECN Changed to RGP $0.00 / + (+0.00%) 04/02/20 Resources Connection sees $4M-$5M charge from restructuring initiative 04/02/20 Resources Connection reports Q3 EPS 21c, two estimates 11c 01/02/20 Resources Connection reports Q2 EPS 38c, consensus 30c PFE Pfizer $38.14 / -0.03 (-0.08%) 05/29/20 Pfizer CEO sees compound annual growth rate for revenue at least 6% through 2025 05/10/20 Fly Intel: Top five weekend stock stories 04/28/20 Pfizer backs FY20 adjusted EPS view $2.82-$2.92, consensus $2.86 04/28/20 Pfizer reaffirms FY20 guidance for adjusted EPS, revenue NXTC NextCure $31.20 / -1.96 (-5.91%) 05/07/20 NextCure reports Q1 EPS 35c, consensus (44c) MRSN Mersana Therapeutics $22.55 / +2.85 (+14.47%) 05/08/20 Mersana Therapeutics reports Q1 EPS (35c), consensus (37c) 02/28/20 Mersana Therapeutics reports Q4 EPS (34c), consensus (38c) MRK Merck $80.85 / +1.83 (+2.32%) 04/28/20 Merck cuts FY20 EPS view to $5.17-$5.37 from $5.62-$5.77, consensus $5.56 04/28/20 Merck reports Q1 EPS $1.50, consensus $1.34 04/27/20 Notable companies reporting before tomorrow's open 04/27/20 Fly Intel: What to watch in Merck earnings report KURA Kura Oncology $17.09 / +0.38 (+2.27%) 05/04/20 Kura Oncology reports Q1 EPS (42c), consensus (42c) 02/25/20 Kura Oncology reports Q4 EPS (39c), consensus (41c) KPTI Karyopharm $18.49 / -0.31 (-1.65%) 05/05/20 Karyopharm reports Q1 EPS (78c), consensus (69c) 02/13/20 Karyopharm reports Q4 EPS (76c), consensus (67c) 01/13/20 Karyopharm sees FY19 XPOVIO product sales $30M-$31M 01/13/20 Karyopharm sees Q4 XPOVIO product sales $17M-$18M HALO Halozyme $24.26 / +0.79 (+3.37%) 05/11/20 Halozyme backs FY20 GAAP EPS view of 60c-75c, consensus 62c 05/11/20 Halozyme reports Q1 EPS (4c), consensus (2c) 02/24/20 Halozyme backs FY20 GAAP EPS view 60c-75, consensus 58c 02/24/20 Halozyme reports Q4 EPS (24c), consensus (15c) EXEL Exelixis $24.68 / +0.35 (+1.44%) 05/05/20 Exelixis sees FY20 revenue $850M-$900M, consensus $886.93M. 05/05/20 Exelixis reports Q1 adjusted EPS 19c, consensus 13c 02/25/20 Exelixis reports Q4 EPS 26c, consensus 16c 01/12/20 Exelixis sees FY20 revenue $850M-$900M, consensus $1B DCPH Deciphera $58.47 / +1.53 (+2.69%) 05/05/20 Deciphera reports Q1 EPS ($1.36), consensus ($1.25) 03/09/20 Deciphera reports Q4 EPS ($1.31), consensus ($1.18) CGEN Compugen $15.50 / +3.13 (+25.30%) 05/06/20 Compugen reports Q1 EPS (10c), consensus (10c) 02/20/20 Compugen reports Q4 EPS (10c), consensus (11c) BPMC Blueprint Medicines $65.16 / -1.84 (-2.75%) 05/06/20 Blueprint Medicines reports Q1 EPS ($2.11), consensus ($2.17) 02/13/20 Blueprint Medicines reports Q4 EPS ($1.35), consensus ($1.69) BMY Bristol-Myers $59.72 / -0.08 (-0.13%) 05/07/20 Bristol-Myers sees FY20 revenue $40B-$42B, consensus $41.65B 05/07/20 Bristol-Myers affirms FY21 adjusted EPS view $7.15-$7.45, consensus $7.38 05/07/20 Bristol-Myers affirms FY20 adjusted EPS view $6.00-$5.20, consensus $6.17 05/07/20 Bristol-Myers reports Q1 adjusted EPS $1.72, consensus $1.49 BLUE Bluebird Bio $63.63 / +2.82 (+4.64%) 05/11/20 Bluebird Bio reports Q1 EPS ($3.64), consensus ($4.01) 02/18/20 Bluebird Bio reports Q4 EPS ($4.04), consensus ($3.79) BCYC Bicycle Therapeutics $17.50 / -0.785 (-4.29%) 05/07/20 Bicycle Therapeutics reports Q1 EPS (63c), consensus 11c 03/10/20 Bicycle Therapeutics reports Q4 EPS (25c), consensus (52c) AZN AstraZeneca $54.60 / +1.1 (+2.06%) 02/14/20 AstraZeneca sees FY20 core EPS to increase by mid- to high-teens percentage 02/14/20 AstraZeneca reports Q4 core EPS 89c, consensus 98c 01/08/20 Veracyte announces biopharmaceutical collaboration with Acerta Pharma AVEO Aveo Pharmaceuticals $8.14 / -1.08 (-11.71%) 04/30/20 Aveo Pharmaceuticals reports Q1 EPS (52c), consensus (50c) 03/16/20 Aveo Pharmaceuticals reports Q4 EPS (28c), consensus (59c) ATNX Athenex $10.91 / -0.21 (-1.89%) 05/07/20 Athenex reports Q1 EPS (24c), consensus (17c) 02/27/20 Athenex reports Q4 EPS (28c), consensus (31c) AMGN Amgen $230.13 / +6.11 (+2.73%) 04/30/20 Amgen backs FY20 adjusted EPS view $14.85-$15.60, consensus $15.42 04/30/20 Amgen reports Q1 adjusted EPS $4.17, consensus $3.76 04/30/20 Notable companies reporting after market close 04/29/20 Fly Intel: What to watch in large-cap biotech earnings reports ALLO Allogene Therapeutics $48.08 / +1.48 (+3.18%) 05/06/20 Allogene Therapeutics reports Q1 EPS (50c), consensus (58c) 02/27/20 Allogene Therapeutics reports Q4 EPS (58c), consensus (68c) ABBV AbbVie $92.78 / +2.77 (+3.08%) 05/01/20 AbbVie sees Q2 adjusted EPS $2.10-$2.16, consensus $2.25 05/01/20 AbbVie backs FY20 adjusted EPS view $9.61-$9.71, consensus $9.48 05/01/20 AbbVie reports Q1 adjusted EPS $2.42, consensus $2.25 04/30/20 Notable companies reporting before tomorrow's open TRIL PFE MRK BMY AZN AMGN ABBV TRIL Trillium Therapeutics $6.76 / +0.995 (+17.26%) 03/11/20 Trillium could be 'compelling' target after Forty Seven deal, Dealreporter says PFE Pfizer $38.14 / -0.03 (-0.08%) 05/17/20 Coronavirus vaccine front-runners emerge, WSJ says 05/16/20 Too early to pick winners, losers in COVID-19 vaccine race, Barron's says 05/10/20 Pfizer to outsource some drug production, focus on COVID vaccine, Reuters says 05/05/20 ICE partners with Amazon, 3M to identify counterfeit coronavirus gear, WSJ says MRK Merck $80.85 / +1.83 (+2.32%) 05/26/20 Merck CEO: 12-18 month COVID vaccine timeline 'very aggressive,' FT reports 05/22/20 U.S. plans 'massive' vaccine testing with over 100,000 patients, Reuters says BMY Bristol-Myers $59.72 / -0.08 (-0.13%) 02/01/20 Oracle, Discovery still looking cheap, Barron's says 01/03/20 Novartis, Merck, Allergan raise U.S. prices on over 100 drugs, Reuters reports 12/13/19 Bristol-Myers awarded $585M in damages in patent win over Gilead, Bloomberg says 12/13/19 Bristol-Myers awarded $585M in damages in patent win over Gilead, Bloomberg says AZN AstraZeneca $54.60 / +1.1 (+2.06%) 05/29/20 AstraZeneca may consider exposing trial participants to virus, Reuters reports 05/27/20 AstraZeneca tests Farxiga as COVID-19 treatment, Reuters reports 05/22/20 U.S. plans 'massive' vaccine testing with over 100,000 patients, Reuters says 05/22/20 Astra-Oxford vaccine may be tested 'side-by-side' with Moderna's, Reuters says AMGN Amgen $230.13 / +6.11 (+2.73%) 05/28/20 Elliott says Alexion settlement may 'leave the door open' for strategic review 03/06/20 Roche bid to block Amgen's Herceptin biosimilar fails, Bloomberg reports 01/07/20 Amgen wins ruling that Amneal's Zydus infringes Sensipar patent, Bloomberg says ABBV AbbVie $92.78 / +2.77 (+3.08%) 03/23/20 AbbVie gives up patent rights for Keltra antiviral treatment, FT reports 03/19/20 AbbVie's Kaletra fails as treatment for severe COVID-19, Reuters reports 03/07/20 J&J, Amgen among healthy dividend stocks as COVID-19 fears grow, Barron's says 03/07/20 AT&T, Dow among dividend stocks to buy amid coronavirus selloff, Barron's says XNCR STML SGEN SBPH PFE MRSN MRK KPTI HALO EXEL DCPH BPMC BMY BLUE BCYC AZN AVEO ATNX AMGN ALLO ABBV XNCR Xencor $30.30 / -0.69 (-2.23%) 05/07/20 Fly Intel: After-Hours Movers STML Stemline $11.89 / + (+0.00%) 05/04/20 Fly Intel: Wall Street's top stories for Monday 05/04/20 Fly Intel: Wall Street's top stories at midday 05/04/20 Fly Intel: Pre-market Movers SGEN Seattle Genetics $157.30 / +5.53 (+3.64%) 05/01/20 Fly Intel: Gilead, Beyond Meat downgrades among today's top calls on Wall Street 04/30/20 Fly Intel: After-Hours Movers SBPH Spring Bank Pharmaceuticals $1.66 / +0.015 (+0.91%) 12/30/19 Bullish takes on Chipotle, Crowdstrike among today's top Wall Street calls 12/27/19 Downgrades of Spring Bank, Darden among today's top analyst calls 12/26/19 Fly Intel: Wall Street's top stories for Thursday 12/26/19 Fly Intel: Wall Street's top stories at midday PFE Pfizer $38.14 / -0.03 (-0.08%) 05/15/20 Fly Intel: Wall Street's top stories for Friday 05/15/20 Sarepta jumps after Pfizer announces DMD gene therapy data 05/05/20 Fly Intel: Wall Street's top stories for Tuesday 05/05/20 Fly Intel: Wall Street's top stories at midday MRSN Mersana Therapeutics $22.55 / +2.85 (+14.47%) 05/27/20 Fly Intel: Wall Street's top stories for Wednesday 04/13/20 Fly Insider: Carnival, SBA among week's notable insider transactions MRK Merck $80.85 / +1.83 (+2.32%) 05/26/20 Fly Intel: Wall Street's top stories for Tuesday 05/26/20 Fly Intel: Wall Street's top stories at midday 05/26/20 Fly Intel: Pre-market Movers KPTI Karyopharm $18.49 / -0.31 (-1.65%) 05/28/20 Fly Intel: After-Hours Movers 05/05/20 Fly Intel: Pre-market Movers 03/03/20 Fly Intel: Pre-market Movers HALO Halozyme $24.26 / +0.79 (+3.37%) 05/11/20 Fly Intel: After-Hours Movers EXEL Exelixis $24.68 / +0.35 (+1.44%) 04/20/20 Fly Intel: Wall Street's top stories for Monday 04/20/20 Fly Intel: Wall Street's top stories at midday 04/20/20 Fly Intel: Pre-market Movers DCPH Deciphera $58.47 / +1.53 (+2.69%) 03/12/20 Before the Move: Watch Blueprint Medicines into Phase 2 trial update BPMC Blueprint Medicines $65.16 / -1.84 (-2.75%) 04/28/20 Fly Intel: Wall Street's top stories for Tuesday 04/28/20 Fly Intel: Wall Street's top stories at midday 04/28/20 Fly Intel: Pre-market Movers BMY Bristol-Myers $59.72 / -0.08 (-0.13%) 05/26/20 Fly Intel: After-Hours Movers 05/07/20 Fly Intel: Pre-market Movers 05/06/20 Novo Nordisk slips as analysts discuss NASH data, read-through to peers BLUE Bluebird Bio $63.63 / +2.82 (+4.64%) 05/18/20 Fly Intel: Pre-market Movers 05/13/20 Fly Intel: Pre-market Movers BCYC Bicycle Therapeutics $17.50 / -0.785 (-4.29%) 03/10/20 Fly Intel: Pre-market Movers AZN AstraZeneca $54.60 / +1.1 (+2.06%) 05/23/20 Week in Review: How Trump's policies moved stocks 03/24/20 Innate rises again on potential use of cancer drug against COVID-19 03/02/20 Larger coronavirus drag on U.S. growth seen as analysts discuss further impact 01/13/20 Amarin jumps after AstraZeneca fish oil drug trial fails AVEO Aveo Pharmaceuticals $8.14 / -1.08 (-11.71%) 05/29/20 Fly Intel: Pre-market Movers 03/31/20 Fly Intel: After-Hours Movers ATNX Athenex $10.91 / -0.21 (-1.89%) 12/30/19 Fly Insider: Kodak, Quotient among week's notable insider trades 12/13/19 Fly Intel: Wall Street's top stories for Friday 12/13/19 Fly Intel: Wall Street's top stories at midday AMGN Amgen $230.13 / +6.11 (+2.73%) 05/28/20 Alexion rises as documents suggest settlement of Amgen patent challenge 05/28/20 Fly Intel: Pre-market Movers 03/30/20 Fly Intel: Alphabet upgrade among today's top calls on Wall Street 03/12/20 Piper sees trial disruption risk, calls out Moderna, Inovio as 'COVID-19 plays' ALLO Allogene Therapeutics $48.08 / +1.48 (+3.18%) 05/14/20 Fly Intel: Wall Street's top stories for Thursday 05/14/20 Allogene jumps, Compugen plunges following release of cancer meeting abstracts 05/14/20 Fly Intel: Pre-market Movers 05/13/20 Fly Intel: After-Hours Movers ABBV AbbVie $92.78 / +2.77 (+3.08%) 05/12/20 CarMax upgrade, Chevron downgrade among today's top calls on Wall Street 03/20/20 Inovio, Moderna gain ahead of Sunday's 60 Minutes report on COVID-19 vaccines 03/18/20 COVID-19 drug seen as possible this year, vaccine in 2021 as crisis continues 02/07/20 Fly Intel: Wall Street's top stories for Friday 07/31/20 Merck - MRK 06/04/20 PDUFA Date for RECARBRIO 06/16/20 PDUFA Date for KEYTRUDA 06/23/20 PDUFA Date for Oral XPOVIO (Selinexor) Tablets 08/06/20 PDUFA Date for CM-9LA Opdivo + Yervoy 08/13/20 PDUFA Date for Ripretinib 08/17/20 PDUFA Date for Lisocabtagene Maraleucel (liso-cel) 08/20/20 PDUFA Date for Tucantinib 09/03/20 PDUFA Date for CC-486 11/15/20 PDUFA Date 12/30/20 PDUFA Date for Tirbanibulin Ointment 06/01/20 Compugen 06/05/20 Athenex, Inc. 06/05/20 Allogene Therapeutics, Inc. 06/10/20 Deciphera Pharmaceuticals, Inc. 06/10/20 AVEO Pharmaceuticals, Inc. 06/11/20 NextCure, Inc. 06/11/20 Syros Pharmaceuticals, Inc. 06/12/20 Mersana Therapeutics, Inc. 06/18/20 bluebird bio, Inc. 06/23/20 Blueprint Medicines Corp. 06/24/20 Spring Bank Pharmaceuticals, Inc. 06/24/20 Kura Oncology, Inc. 06/25/20 Xencor, Inc. 06/30/20 Trillium Therapeutics Inc. TRIL RECN PFE MRSN MRK EXEL BMY AZN ABBV TRIL Trillium Therapeutics $6.76 / +0.995 (+17.26%) 05/05/20 Largest borrow rate increases among liquid names 04/03/20 Largest borrow rate increases among liquid names 02/11/20 Largest borrow rate increases among liquid names 02/05/20 Largest borrow rate increases among liquid names RECN Changed to RGP $0.00 / + (+0.00%) 04/02/20 Three new option listings and four option delistings on April 2nd PFE Pfizer $38.14 / -0.03 (-0.08%) 05/05/20 Unusually active option classes on open May 5th 04/28/20 Unusually active option classes on open April 28th 04/06/20 Unusual call flow in option market yesterday 04/03/20 Opening call sale in Pfizer struck 7.4% above spot MRSN Mersana Therapeutics $22.55 / +2.85 (+14.47%) 02/12/20 Four new option listings and one option delisting on February 12th MRK Merck $80.85 / +1.83 (+2.32%) 05/14/20 Early notable gainers among liquid option names on May 14th 04/09/20 Merck call volume above normal and directionally bullish 02/05/20 Unusually active option classes on open February 5th EXEL Exelixis $24.68 / +0.35 (+1.44%) 05/11/20 Exelixis call volume above normal and directionally bullish 05/08/20 Exelixis call volume above normal and directionally bullish 03/06/20 Exelixis call volume above normal and directionally bullish 02/18/20 Exelixis put volume heavy and directionally bearish BMY Bristol-Myers $59.72 / -0.08 (-0.13%) 05/01/20 Bristol Myers Squibb put volume heavy and directionally bearish 04/20/20 Bristol Myers Squibb call volume above normal and directionally bullish 04/20/20 Early notable gainers among liquid option names on April 20th 03/30/20 Unusually active option classes on open March 30th AZN AstraZeneca $54.60 / +1.1 (+2.06%) 05/28/20 Unusually active option classes on open May 28th 05/27/20 AstraZeneca call volume above normal and directionally bullish 05/22/20 Unusually active option classes on open May 22nd ABBV AbbVie $92.78 / +2.77 (+3.08%) 05/19/20 Unusually active option classes on open May 19th 05/12/20 Early notable gainers among liquid option names on May 12th 05/12/20 Unusually active option classes on open May 12th 02/07/20 Early notable gainers among liquid option names on February 7th
Conference/Events	American Society of Clinical Oncology (ASCO) to hold virtual meeting » 04:55 05/30/20 05/30 04:55 05/30/20 04:55 ABBV AbbVie $92.78 / +2.77 (+3.08%) , ALLO Allogene Therapeutics $48.08 / +1.48 (+3.18%) , AMGN Amgen $230.13 / +6.11 (+2.73%) , ATNX Athenex $10.91 / -0.21 (-1.89%) , AVEO Aveo Pharmaceuticals $8.14 / -1.08 (-11.71%) , AZN AstraZeneca $54.60 / +1.1 (+2.06%) , BCYC Bicycle Therapeutics $17.50 / -0.785 (-4.29%) , BLUE Bluebird Bio $63.63 / +2.82 (+4.64%) , BPMC Blueprint Medicines $65.16 / -1.84 (-2.75%) , CGEN Compugen $15.50 / +3.13 (+25.30%) , HALO Halozyme $24.26 / +0.79 (+3.37%) , EXEL Exelixis $24.68 / +0.35 (+1.44%) , DCPH Deciphera $58.47 / +1.53 (+2.69%) , KURA Kura Oncology $17.09 / +0.38 (+2.27%) , KPTI Karyopharm $18.49 / -0.31 (-1.65%) , MRK Merck $80.85 / +1.83 (+2.32%) , BMY Bristol-Myers $59.72 / -0.08 (-0.13%) , MRSN Mersana Therapeutics $22.55 / +2.85 (+14.47%) , NXTC NextCure $31.20 / -1.96 (-5.91%) , PFE Pfizer $38.14 / -0.03 (-0.08%) , RECN Changed to RGP $0.00 / + (+0.00%) , REPL Replimune Group $18.85 / +0.3 (+1.62%) , SBPH Spring Bank Pharmaceuticals $1.66 / +0.015 (+0.91%) , SGEN Seattle Genetics $157.30 / +5.53 (+3.64%) , STML Stemline $11.89 / + (+0.00%) , SYRS Syros Pharmaceuticals $9.77 / +0.25 (+2.63%) , TRIL Trillium Therapeutics $6.76 / +0.995 (+17.26%) , TROV Changed name to CRDF $0.00 / + (+0.00%) , XNCR Xencor $30.30 / -0.69 (-2.23%) Virtual Annual Meeting of… Virtual Annual Meeting of ASCO 2020 will be held on May 29-31. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options XNCR TROV TRIL SYRS STML SGEN SBPH REPL RECN PFE NXTC MRSN MRK KURA KPTI HALO EXEL DCPH CGEN BPMC BMY BLUE BCYC AZN AVEO ATNX AMGN ALLO ABBV XNCR Xencor $30.30 / -0.69 (-2.23%) 05/13/20 Xencor reports initial dose escalation in ph1 study of XmAb20717 03/25/20 Xencor, Vir Biotechnology enter license agreement for use of Xtend in Covid-19 03/24/20 Exagen appoints Debra Jeske Zack as CMO, Anja Kammesheidt as CSO 02/05/20 Aimmune obtains license for XmAb7195 from Xencor for $5M in cash, $5M in equity TROV Changed name to CRDF $0.00 / + (+0.00%) 05/06/20 Trovagene changing company name to Cardiff Oncology, appoints Mark Erlander CEO 04/28/20 Trovagene announces results from Phase 1b/2 clinical trial of onvansertib 02/13/20 Trovagene presents Phase 2 efficacy data on onvansertib for mCRPC 01/29/20 Trovagene receives approximately $1.45M from exercise of warrants TRIL Trillium Therapeutics $6.76 / +0.995 (+17.26%) 05/29/20 Trillium updates dose escalation sudy of CD47 Blocker TTI-622 at ASCO 05/06/20 Trillium Therapeutics announces ATM equity program 04/08/20 Trillium Therapeutics says difficult to predict COVID-19 impact 04/08/20 Trillium Therapeutics says cash runway 'sufficient' into 2022 SYRS Syros Pharmaceuticals $9.77 / +0.25 (+2.63%) 05/29/20 Syros Pharmaceuticals presents new preclinical data for SY-5609 at ASCO 04/02/20 Point72 discloses 5.1% passive stake in Syros Pharmaceuticals 01/29/20 Syros Pharmaceuticals announces preclinical data on CDK7, CDK12 01/28/20 Syros Pharmaceuticals doses first patient in SY-5609 Phase 1 clinical trial STML Stemline $11.89 / + (+0.00%) 05/04/20 Stemline trading resumes 05/04/20 Menarini Group to acquire Stemline in transaction valued at up to $677M 05/04/20 Stemline trading halted, news pending 01/13/20 Fly Intel: After Hours Movers SGEN Seattle Genetics $157.30 / +5.53 (+3.64%) 05/29/20 Seattle Genetics announces results from exploratory analyses of HER2CLIMB trial 05/14/20 Takeda Pharmaceutical receives EC approval for Adcetris MA extension 05/12/20 Seattle Genetics Tukysa receives Swiss Agency for Therapeutic Products approval 04/30/20 Seattle Genetics sees FY20 ADCETRIS net product sales $675M-$700M SBPH Spring Bank Pharmaceuticals $1.66 / +0.015 (+0.91%) 04/02/20 Spring Bank Pharmaceuticals continues trial for IB SB 11285 04/02/20 Spring Bank says safety committee for SB 11285 trial recommends dose escalation 02/25/20 Spring Bank, Roche announces collaboration to evaluate SB 11285 w/ atezolizumab 01/29/20 Spring Bank down 4.5% after discontinuing development of inarigivir soproxil REPL Replimune Group $18.85 / +0.3 (+1.62%) 04/02/20 Replimune Group appoints Dieter Weinand as chairman of the board 02/13/20 Replimune Group 'on track' to initiate Phase 1 trial of RP3 in 2020 02/13/20 Replimune Group expects inital data from Phase 1 trial of RP2 by end of 2020 02/13/20 Replimune Group 'on track' to initiate Phase 1/2 trial of RP1 in 1H20 RECN Changed to RGP $0.00 / + (+0.00%) 03/30/20 Resources Connection to change trading symbol to 'RGP' 02/04/20 Resources Connection names Jennifer Ryu as new CFO 01/03/20 Resources Connections rises after upbeat Q2 earnings 01/02/20 Fly Intel: After Hours Movers PFE Pfizer $38.14 / -0.03 (-0.08%) 05/29/20 Pfizer shares down 8.4% following Phase 3 PALLAS Ibrance trial update 05/29/20 Pfizer reports Phase 3 PALLAS Ibrance trial unlikely to meet endpoint 05/29/20 Pfizer, Astellas Pharma: PROSPER results show XTANDI 'signifcantly extends' OS 05/28/20 Corning, Pfizer announce supply agreement for Corning Valor Glass Packaging NXTC NextCure $31.20 / -1.96 (-5.91%) 05/29/20 NextCure presents biomarker data, results form NC318 trial at ASCO 04/13/20 NextCure temporarily delays start of NC410 Phase 1/2 trial 04/13/20 NextCure expects data from Phase 2 of Phase 1/2 NC318 trial to be delayed 04/13/20 NextCure temporarily delays start of NC318 combination clinical trial MRSN Mersana Therapeutics $22.55 / +2.85 (+14.47%) 05/27/20 Mersana Therapeutics reports interim Phase 1 data for XMT-1536 cancer candidate 05/14/20 Mersana Therapeutics initiates patient dosing in XMT-1592 dose escalation study 05/13/20 Mersana Therapeutics to report interim data from Phase 1 dose expansion of XMT-1 04/15/20 Mersana Therapeutics appoints Martin Huber to board of directors MRK Merck $80.85 / +1.83 (+2.32%) 05/28/20 Merck, Eisai announce new data from KEYTRUDA plus LENVIMA trials 05/28/20 Merck study shows KEYTRUDA reduced risk of progression, death by 40% 05/26/20 Merck jumps 2.5% in premarket trading on plans for COVID-19 vaccines, treatment 05/26/20 Merck, Ridgeback Bio collaborate to advance development of EIDD-2801 KURA Kura Oncology $17.09 / +0.38 (+2.27%) 05/29/20 Kura reports data from tipifarnib study of metastatic HRAS mutant HNSCC 03/03/20 Kura Oncology receives Fast Track designation for tipifarnib in T-cell lymphomas 01/23/20 Kura Oncology appoints Bridget Martell acting Chief Medical Officer 01/06/20 Kura Oncology appoints Kirsten Flowers as CCO KPTI Karyopharm $18.49 / -0.31 (-1.65%) 05/28/20 Karyopharm reports Phase 3 Boston data in ASCO presentation 05/20/20 Karyopharm submits sNDA to FDA for XPOVIO 05/13/20 Karyopharm donates 60,000 medical masks across Massachusetts, the U.S. 05/05/20 Antengene broadens partnership with Karyopharm HALO Halozyme $24.26 / +0.79 (+3.37%) 05/14/20 Halozyme to receive $15M milestone payment from Johnson & Johnson's Janssen 05/01/20 Halozyme announces FDA approval of DARZALEX FASPRO for Janssen Biotech 04/30/20 Halozyme discloses Janssen receipt CHMP positive opinion for Darzalex 04/27/20 Halozyme announces daratumumab NDA filed in Japan by Janssen EXEL Exelixis $24.68 / +0.35 (+1.44%) 05/13/20 Exelixis to present ph. 1b trial results for cabozantinib+atezolizumab as ASCO 04/20/20 Bristol-Myers, Exelixis: CheckMate-9ER met primary endpoint of PFS 03/25/20 Exelixis says Takeda Pharmaceutical receives approval in Japan for CABOMETYX 02/25/20 Fly Intel: After Hours Movers DCPH Deciphera $58.47 / +1.53 (+2.69%) 05/29/20 Deciphera presents results from INVICTUS pivotal Phase 3 study at ASCO 05/29/20 Deciphera presents data from cohort of Part 2 of rebastinib Phase 1b/2 at ASCO 05/15/20 Deciphera announces FDA approval of QINLOCK for treatment of GIST 05/15/20 Deciphera up over 5% after receiving FDA approval for ripretinib in 4L+GIST CGEN Compugen $15.50 / +3.13 (+25.30%) 05/27/20 Compugen doses first patient in COM701 Phase 1 monotherapy expansion cohort 04/22/20 Compugen granted patent in Europe for backup cancer antibodies 04/20/20 Compugen and Bayer's BAY 1905254 study results published in reviewed paper 04/06/20 Compugen: First patient dosed in COM902 Phase 1 trial BPMC Blueprint Medicines $65.16 / -1.84 (-2.75%) 05/29/20 Blueprint Medicines presents data from ARROW clinical trial of pralsetinib 05/15/20 Blueprint Medicines receives CRL from FDA on NDA for avapritinib 05/06/20 Blueprint Medicines: Cash sufficient to fund operating expenses to 2H22 04/28/20 Blueprint Medicines trading resumes BMY Bristol-Myers $59.72 / -0.08 (-0.13%) 05/29/20 Heat Biologics presents HS-110/Opdivo combination Phase 2 trial data at ASCO 05/28/20 WindMIL doses first patient in Phase 2 study of MILs in combo w/ nivolumab 05/27/20 TCR2 Therapeutics appoints Gregg McConnell as head of business development BLUE Bluebird Bio $63.63 / +2.82 (+4.64%) 05/29/20 Bristol-Myers CEO says 'very much on track' with ide-cel resubmission 05/13/20 Bluebird Bio, Bristol-Myers to update results from KarMMa Study of Ide-cel 05/13/20 Bluebird sinks after FDA issues Refusal to File letter for myeloma treatment 05/13/20 Bristol-Myers, Bluebird Bio receive RTF letter on BLA for idecabtagene vicleucel BCYC Bicycle Therapeutics $17.50 / -0.785 (-4.29%) 05/05/20 Bicycle announces dosing of first patient in Phase I study of BT5528 04/07/20 Bicycle Therapeutics expects to reach 2020 milestones as planned 03/12/20 Bicycle Therapeutics PLC (ADS) trading resumes 03/12/20 Bicycle Therapeutics PLC (ADS) trading halted, volatility trading pause AZN AstraZeneca $54.60 / +1.1 (+2.06%) 05/29/20 AstraZeneca reports results from updated CASPIAN trial analysis 05/29/20 AstraZeneca says Imfinzi showed sustained overall survival benefit 05/29/20 AstraZeneca announces results from Imfinzi plus tremelimumab trial 05/29/20 AstraZeneca says Enhertu improved overall survival in gastric cancer trial AVEO Aveo Pharmaceuticals $8.14 / -1.08 (-11.71%) 05/29/20 Aveo Pharmaceuticals DEDUCTIVE trial advances to Phase 2 portion 05/29/20 Aveo presents results from final analysis of Phase 3 TIVO-3 trial 03/31/20 Aveo submits NDA to FDA for tivozanib 03/27/20 Aveo Oncology discontinues CyFi-2 study due to impact of COVID-19 ATNX Athenex $10.91 / -0.21 (-1.89%) 05/29/20 Athenex presents interim data from oral paclitaxel Phase II study 05/07/20 Athenex sees 2020 y-o-y product sales growth in mid-single digits 05/07/20 Athenex announces upcoming milestones 05/07/20 Athenex expects cash, cash equivalents to fund operations into 1Q21 AMGN Amgen $230.13 / +6.11 (+2.73%) 05/29/20 Amgen presents new AMG 510 clinical data 05/08/20 Cytokinetics, Amgen granted Fast Track designation for omecamtiv mecarbil 05/08/20 Amgen,Cytokinetics: FDA grants Fast Track designation for omecamtiv mecarbil 05/06/20 Amgen reports 'positive' results from Otezla Phase 3 ADVANCE study ALLO Allogene Therapeutics $48.08 / +1.48 (+3.18%) 05/29/20 Allogene Therapeutics reports results from Phase 1 ALPHA study of ALLO-501 05/26/20 Allogene Therapeutics announces webinar to review initial ALLO-501 phase 1 data 05/13/20 Allogene Therapeutics jumps 32% after reporting ALLO-501 data 05/06/20 Allogene Therapeutics expects 2020 net losses $260M-$280M ABBV AbbVie $92.78 / +2.77 (+3.08%) 05/29/20 FDA announces approval of AbbVie's Oriahnn 05/27/20 Ironwood, AbbVie announce MD-7246 trial did not meet primary endpoint 05/21/20 Synlogic announces termination of IBD treatment collaboration with AbbVie 05/12/20 AbbVie director sells 23K shares of common stock ABBV ALLO AMGN ATNX AVEO AZN BCYC BLUE BPMC CGEN HALO EXEL DCPH KURA KPTI MRK BMY MRSN NXTC PFE RECN REPL SBPH SGEN STML SYRS TRIL TROV XNCR ABBV AbbVie $92.78 / +2.77 (+3.08%) 05/22/20 Piper Sandler Growth of Biohaven's Nurtec continues to beat AbbVie's Ubrelvy, says Piper 05/21/20 Piper Sandler Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration 05/18/20 BofA AbbVie reinstated with a Neutral at BofA 05/12/20 JPMorgan AbbVie resumed with an Overweight from Neutral at JPMorgan ALLO Allogene Therapeutics $48.08 / +1.48 (+3.18%) 05/29/20 H.C. Wainwright Allogene Therapeutics price target raised to $55 from $42 at H.C. Wainwright 05/29/20 Piper Sandler Allogene Therapeutics price target raised to $70 from $50 at Piper Sandler 05/19/20 Roth Capital Allogene Therapeutics upgraded to Buy with $60 target at Roth Capital 05/19/20 Roth Capital Allogene Therapeutics upgraded to Buy from Neutral at Roth Capital AMGN Amgen $230.13 / +6.11 (+2.73%) 05/28/20 Piper Sandler Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler 05/28/20 Cowen Alexion settlement may yield upside surprise, says Cowen 05/28/20 Stifel Alexion, Amgen appear to have agreed to settlement deal, says Stifel 05/22/20 Piper Sandler Harpoon Therapeutics initiated with an Overweight at Piper Sandler ATNX Athenex $10.91 / -0.21 (-1.89%) 12/13/19 RBC Capital Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital 12/06/19 Truist Athenex initiated with a Buy at SunTrust 11/19/19 RBC Capital Athenex gets 'third SABCS win' ahead of meeting, says RBC Capital 08/07/19 RBC Capital Athenex's Oraxol data 'near best-case,' says RBC Capital AVEO Aveo Pharmaceuticals $8.14 / -1.08 (-11.71%) 05/29/20 Piper Sandler Aveo Pharmaceuticals price target raised to $26 from $18.50 at Piper Sandler 05/29/20 Baird Aveo Pharmaceuticals price target raised to $24 from $15 at Baird 05/01/20 H.C. Wainwright Aveo Pharmaceuticals price target raised to $10 from $6 at H.C. Wainwright 04/01/20 H.C. Wainwright Aveo Pharmaceuticals price target raised to $6 from $4 at H.C. Wainwright AZN AstraZeneca $54.60 / +1.1 (+2.06%) 05/29/20 Guggenheim AstraZeneca price target raised to 10,100 GBp from 9,100 GBp at Guggenheim 05/14/20 Evercore ISI Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine 05/06/20 Morgan Stanley AstraZeneca price target raised to 8,630 GBp from 8,600 GBp at Morgan Stanley 05/04/20 Citi Citi opens 'positive catalyst watch' on AstraZeneca BCYC Bicycle Therapeutics $17.50 / -0.785 (-4.29%) 04/17/20 Fly Intel: Top five analyst initiations 04/17/20 H.C. Wainwright Bicycle Therapeutics initiated with a Buy at H.C. Wainwright 04/07/20 Piper Sandler Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler 02/25/20 Piper Sandler Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler BLUE Bluebird Bio $63.63 / +2.82 (+4.64%) 05/13/20 Stifel Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel 05/13/20 Piper Sandler Bluebird should be able to easily address RTF issues, says Piper Sandler 05/12/20 RBC Capital Bluebird Bio initiated with an Outperform at RBC Capital 05/12/20 Oppenheimer Bluebird Bio price target lowered to $111 from $122 at Oppenheimer BPMC Blueprint Medicines $65.16 / -1.84 (-2.75%) 05/29/20 Raymond James Blueprint approval for pralsetinib could come before PDUFA, says Raymond James 05/06/20 Nomura Instinet Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet 05/05/20 Barclays Blueprint Medicines initiated with an Equal Weight at Barclays 04/29/20 SVB Leerink Deciphera price target raised to $55 from $50 at SVB Leerink CGEN Compugen $15.50 / +3.13 (+25.30%) 05/26/20 JMP Securities Compugen resumed with an Outperform at JMP Securities 05/13/20 Fly Intel: Top five analyst initiations 05/13/20 Stifel Compugen initiated with a Buy at Stifel 05/07/20 Fly Intel: Top five analyst initiations HALO Halozyme $24.26 / +0.79 (+3.37%) 05/26/20 Piper Sandler Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler 05/12/20 JMP Securities Halozyme price target raised to $34 from $24 at JMP Securities 05/04/20 Cantor Fitzgerald Halozyme price target raised to $39 from $35 at Cantor Fitzgerald 03/23/20 Citi Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak EXEL Exelixis $24.68 / +0.35 (+1.44%) 05/14/20 Truist Exelixis price target raised to $40 from $35 at SunTrust 05/13/20 Piper Sandler Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler 05/06/20 Piper Sandler Exelixis price target raised to $30 from $23 at Piper Sandler 04/21/20 Guggenheim Exelixis price target raised to $32 from $27 at Guggenheim DCPH Deciphera $58.47 / +1.53 (+2.69%) 05/18/20 Truist Deciphera price target raised to $91 from $82 at SunTrust 05/18/20 Barclays Deciphera price target raised to $85 from $80 at Barclays 05/18/20 Piper Sandler Piper Sandler a buyer of Deciphera shares on the open 05/15/20 Piper Sandler Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler KURA Kura Oncology $17.09 / +0.38 (+2.27%) 05/29/20 Piper Sandler Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler 05/29/20 H.C. Wainwright Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright 05/19/20 Deutsche Bank Kura Oncology price target lowered to $24 from $28 at Deutsche Bank 05/06/20 Wedbush Kura prioritizing development of tipifarnib for HRAS-HNSCC, says Wedbush KPTI Karyopharm $18.49 / -0.31 (-1.65%) 05/06/20 H.C. Wainwright Karyopharm price target lowered to $40 from $43 at H.C. Wainwright 04/07/20 Wedbush Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID 04/07/20 H.C. Wainwright XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright 03/04/20 Barclays Karyopharm initiated with an Overweight at Barclays MRK Merck $80.85 / +1.83 (+2.32%) 05/27/20 Alliance Global Partners PDS Biotechnology initiated with a Buy at Alliance Global Partners 05/20/20 JonesTrading Merck collaboration positions Surface Oncology well, says JonesTrading 04/27/20 SVB Leerink Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades 04/06/20 Raymond James NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James BMY Bristol-Myers $59.72 / -0.08 (-0.13%) 04/20/20 Piper Sandler Exelixis combo approval would increase kidney cancer use, says Piper Sandler MRSN Mersana Therapeutics $22.55 / +2.85 (+14.47%) 05/27/20 H.C. Wainwright Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright 04/29/20 BTIG Mersana Therapeutics initiated with a Buy at BTIG 01/21/20 H.C. Wainwright Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright 08/20/19 H.C. Wainwright H.C. Wainwright says trial initiation at higher dosing 'bodes well' for Mersana NXTC NextCure $31.20 / -1.96 (-5.91%) 05/29/20 Piper Sandler NextCure data shows S15-mediated activity, says Piper Sandler 05/26/20 JMP Securities NextCure initiated with an Outperform at JMP Securities 04/13/20 Piper Sandler NextCure could report Phase I biomarker data at ASCO, says Piper Sandler 03/24/20 Benchmark NextCure initiated with a Buy at Benchmark PFE Pfizer $38.14 / -0.03 (-0.08%) 05/21/20 Piper Sandler Gilead's filgotinib likely being underestimated by Street, says Piper Sandler 05/19/20 H.C. Wainwright BioNTech upgraded to Buy from Neutral at H.C. Wainwright 05/15/20 Goldman Sachs After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy 05/15/20 JPMorgan JPMorgan still sees Sarepta in pole position in DMD space RECN Changed to RGP $0.00 / + (+0.00%) 01/03/20 Baird Resources Connection Q3 guidance 'materially below' expectations, says Baird 10/03/19 JPMorgan Resources Connection near-term outlook remains challenged, says JPMorgan REPL Replimune Group $18.85 / +0.3 (+1.62%) 05/05/20 Barclays Replimune Group initiated with an Overweight at Barclays 03/25/20 Wedbush Replimune Group added to Best Ideas List at Wedbush 11/11/19 Roth Capital Replimune Group price target raised to $30 from $20 at Roth Capital 09/04/19 Roth Capital Replimune Group initiated with a Buy at Roth Capital SBPH Spring Bank Pharmaceuticals $1.66 / +0.015 (+0.91%) 04/02/20 Piper Sandler Piper Sandler keeps Neutral on Spring Bank as study enrollment expected to slow 01/29/20 Jefferies Spring Bank Pharmaceuticals downgraded to Hold from Buy at Jefferies 01/29/20 Piper Sandler Piper keeps Neutral rating on Spring Bank after inarigivir discontinued 12/30/19 Fly Intel: Top five analyst actions SGEN Seattle Genetics $157.30 / +5.53 (+3.64%) 05/26/20 Goldman Sachs Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs 05/26/20 JMP Securities Seattle Genetics initiated with an Outperform at JMP Securities 05/26/20 Goldman Sachs Incyte downgraded to Buy from Conviction Buy at Goldman Sachs 05/26/20 Goldman Sachs Seattle Genetics upgraded to Conviction Buy from Buy at Goldman Sachs STML Stemline $11.89 / + (+0.00%) 05/05/20 H.C. Wainwright Stemline downgraded to Neutral from Buy at H.C. Wainwright 05/05/20 Ladenburg Stemline downgraded to Neutral from Buy at Ladenburg 05/04/20 Alliance Global Partners Stemline downgraded to Neutral from Buy at Alliance Global Partners 05/04/20 Wedbush Stemline downgraded to Neutral from Outperform at Wedbush SYRS Syros Pharmaceuticals $9.77 / +0.25 (+2.63%) 05/29/20 Roth Capital Syros Pharmaceuticals ASCO update bodes well for ph1 data, says Roth Capital 05/29/20 Piper Sandler Syros price target raised to $14 after ASCO update at Piper Sandler 04/23/20 JonesTrading Syros Pharmaceuticals initiated with a Buy at JonesTrading 03/06/20 H.C. Wainwright Syros Pharmaceuticals price target lowered to $8 from $10 at H.C. Wainwright TRIL Trillium Therapeutics $6.76 / +0.995 (+17.26%) 05/26/20 JMP Securities Trillium Therapeutics initiated with an Outperform at JMP Securities 08/19/19 Fly Intel: Top five analyst downgrades 08/19/19 H.C. Wainwright Trillium Therapeutics downgraded to Neutral from Buy at H.C. Wainwright TROV Changed name to CRDF $0.00 / + (+0.00%) 01/28/20 Noble Capital Trovagene resumed with an Outperform at Noble Capital XNCR Xencor $30.30 / -0.69 (-2.23%) 05/13/20 Piper Sandler Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler 03/04/20 Barclays Barclays starts small, mid cap Biotechnology sector with Positive view 03/04/20 Barclays Xencor initiated with an Underweight at Barclays 02/25/20 Guggenheim Xencor upgraded to Buy from Neutral at Guggenheim XNCR TRIL SYRS STML SGEN SBPH REPL RECN PFE NXTC MRSN MRK KURA KPTI HALO EXEL DCPH CGEN BPMC BMY BLUE BCYC AZN AVEO ATNX AMGN ALLO ABBV XNCR Xencor $30.30 / -0.69 (-2.23%) 05/07/20 Xencor reports Q1 EPS (14c), consensus (38c) 02/24/20 Xencor sees ending 2020 with $500M-$550M in cash 02/24/20 Xencor reports Q4 EPS (47c), consensus (41c) TRIL Trillium Therapeutics $6.76 / +0.995 (+17.26%) 05/15/20 Trillium Therapeutics reports Q1 EPS ($1.07), consensus (90c) 03/10/20 Trillium Therapeutics reports FY19 EPS ($1.65) vs. ($2.35) last year SYRS Syros Pharmaceuticals $9.77 / +0.25 (+2.63%) 05/13/20 Syros Pharmaceuticals director Mark Alles bought 10K shares of company stock 05/07/20 Syros Pharmaceuticals reports Q1 EPS (39c), consensus (43c) 03/05/20 Syros Pharmaceuticals reports Q4 EPS (46c), consensus (47c) STML Stemline $11.89 / + (+0.00%) 03/13/20 Stemline Therapeutics reports Q4 EPS (38c), consensus (35c) SGEN Seattle Genetics $157.30 / +5.53 (+3.64%) 04/30/20 Seattle Genetics reports Q1 EPS (98c), consensus (79c) 02/06/20 Seattle Genetics sees 2020 Adcetris net sales $675M-$700M 02/06/20 Seattle Genetics reports Q4 EPS 14c, consensus (45c) 02/06/20 Notable companies reporting after market close SBPH Spring Bank Pharmaceuticals $1.66 / +0.015 (+0.91%) 02/14/20 Spring Bank Pharmaceuticals reports Q4 EPS (45c), consensus (67c) REPL Replimune Group $18.85 / +0.3 (+1.62%) 02/13/20 Replimune Group reports Q3 EPS (46c), consensus (36c) RECN Changed to RGP $0.00 / + (+0.00%) 04/02/20 Resources Connection sees $4M-$5M charge from restructuring initiative 04/02/20 Resources Connection reports Q3 EPS 21c, two estimates 11c 01/02/20 Resources Connection reports Q2 EPS 38c, consensus 30c PFE Pfizer $38.14 / -0.03 (-0.08%) 05/29/20 Pfizer CEO sees compound annual growth rate for revenue at least 6% through 2025 05/10/20 Fly Intel: Top five weekend stock stories 04/28/20 Pfizer backs FY20 adjusted EPS view $2.82-$2.92, consensus $2.86 04/28/20 Pfizer reaffirms FY20 guidance for adjusted EPS, revenue NXTC NextCure $31.20 / -1.96 (-5.91%) 05/07/20 NextCure reports Q1 EPS 35c, consensus (44c) MRSN Mersana Therapeutics $22.55 / +2.85 (+14.47%) 05/08/20 Mersana Therapeutics reports Q1 EPS (35c), consensus (37c) 02/28/20 Mersana Therapeutics reports Q4 EPS (34c), consensus (38c) MRK Merck $80.85 / +1.83 (+2.32%) 04/28/20 Merck cuts FY20 EPS view to $5.17-$5.37 from $5.62-$5.77, consensus $5.56 04/28/20 Merck reports Q1 EPS $1.50, consensus $1.34 04/27/20 Notable companies reporting before tomorrow's open 04/27/20 Fly Intel: What to watch in Merck earnings report KURA Kura Oncology $17.09 / +0.38 (+2.27%) 05/04/20 Kura Oncology reports Q1 EPS (42c), consensus (42c) 02/25/20 Kura Oncology reports Q4 EPS (39c), consensus (41c) KPTI Karyopharm $18.49 / -0.31 (-1.65%) 05/05/20 Karyopharm reports Q1 EPS (78c), consensus (69c) 02/13/20 Karyopharm reports Q4 EPS (76c), consensus (67c) 01/13/20 Karyopharm sees FY19 XPOVIO product sales $30M-$31M 01/13/20 Karyopharm sees Q4 XPOVIO product sales $17M-$18M HALO Halozyme $24.26 / +0.79 (+3.37%) 05/11/20 Halozyme backs FY20 GAAP EPS view of 60c-75c, consensus 62c 05/11/20 Halozyme reports Q1 EPS (4c), consensus (2c) 02/24/20 Halozyme backs FY20 GAAP EPS view 60c-75, consensus 58c 02/24/20 Halozyme reports Q4 EPS (24c), consensus (15c) EXEL Exelixis $24.68 / +0.35 (+1.44%) 05/05/20 Exelixis sees FY20 revenue $850M-$900M, consensus $886.93M. 05/05/20 Exelixis reports Q1 adjusted EPS 19c, consensus 13c 02/25/20 Exelixis reports Q4 EPS 26c, consensus 16c 01/12/20 Exelixis sees FY20 revenue $850M-$900M, consensus $1B DCPH Deciphera $58.47 / +1.53 (+2.69%) 05/05/20 Deciphera reports Q1 EPS ($1.36), consensus ($1.25) 03/09/20 Deciphera reports Q4 EPS ($1.31), consensus ($1.18) CGEN Compugen $15.50 / +3.13 (+25.30%) 05/06/20 Compugen reports Q1 EPS (10c), consensus (10c) 02/20/20 Compugen reports Q4 EPS (10c), consensus (11c) BPMC Blueprint Medicines $65.16 / -1.84 (-2.75%) 05/06/20 Blueprint Medicines reports Q1 EPS ($2.11), consensus ($2.17) 02/13/20 Blueprint Medicines reports Q4 EPS ($1.35), consensus ($1.69) BMY Bristol-Myers $59.72 / -0.08 (-0.13%) 05/07/20 Bristol-Myers sees FY20 revenue $40B-$42B, consensus $41.65B 05/07/20 Bristol-Myers affirms FY21 adjusted EPS view $7.15-$7.45, consensus $7.38 05/07/20 Bristol-Myers affirms FY20 adjusted EPS view $6.00-$5.20, consensus $6.17 05/07/20 Bristol-Myers reports Q1 adjusted EPS $1.72, consensus $1.49 BLUE Bluebird Bio $63.63 / +2.82 (+4.64%) 05/11/20 Bluebird Bio reports Q1 EPS ($3.64), consensus ($4.01) 02/18/20 Bluebird Bio reports Q4 EPS ($4.04), consensus ($3.79) BCYC Bicycle Therapeutics $17.50 / -0.785 (-4.29%) 05/07/20 Bicycle Therapeutics reports Q1 EPS (63c), consensus 11c 03/10/20 Bicycle Therapeutics reports Q4 EPS (25c), consensus (52c) AZN AstraZeneca $54.60 / +1.1 (+2.06%) 02/14/20 AstraZeneca sees FY20 core EPS to increase by mid- to high-teens percentage 02/14/20 AstraZeneca reports Q4 core EPS 89c, consensus 98c 01/08/20 Veracyte announces biopharmaceutical collaboration with Acerta Pharma AVEO Aveo Pharmaceuticals $8.14 / -1.08 (-11.71%) 04/30/20 Aveo Pharmaceuticals reports Q1 EPS (52c), consensus (50c) 03/16/20 Aveo Pharmaceuticals reports Q4 EPS (28c), consensus (59c) ATNX Athenex $10.91 / -0.21 (-1.89%) 05/07/20 Athenex reports Q1 EPS (24c), consensus (17c) 02/27/20 Athenex reports Q4 EPS (28c), consensus (31c) AMGN Amgen $230.13 / +6.11 (+2.73%) 04/30/20 Amgen backs FY20 adjusted EPS view $14.85-$15.60, consensus $15.42 04/30/20 Amgen reports Q1 adjusted EPS $4.17, consensus $3.76 04/30/20 Notable companies reporting after market close 04/29/20 Fly Intel: What to watch in large-cap biotech earnings reports ALLO Allogene Therapeutics $48.08 / +1.48 (+3.18%) 05/06/20 Allogene Therapeutics reports Q1 EPS (50c), consensus (58c) 02/27/20 Allogene Therapeutics reports Q4 EPS (58c), consensus (68c) ABBV AbbVie $92.78 / +2.77 (+3.08%) 05/01/20 AbbVie sees Q2 adjusted EPS $2.10-$2.16, consensus $2.25 05/01/20 AbbVie backs FY20 adjusted EPS view $9.61-$9.71, consensus $9.48 05/01/20 AbbVie reports Q1 adjusted EPS $2.42, consensus $2.25 04/30/20 Notable companies reporting before tomorrow's open 29 May TRIL PFE MRK BMY AZN AMGN ABBV TRIL Trillium Therapeutics $6.76 / +0.995 (+17.26%) 03/11/20 Trillium could be 'compelling' target after Forty Seven deal, Dealreporter says PFE Pfizer $38.14 / -0.03 (-0.08%) 05/17/20 Coronavirus vaccine front-runners emerge, WSJ says 05/16/20 Too early to pick winners, losers in COVID-19 vaccine race, Barron's says 05/10/20 Pfizer to outsource some drug production, focus on COVID vaccine, Reuters says 05/05/20 ICE partners with Amazon, 3M to identify counterfeit coronavirus gear, WSJ says MRK Merck $80.85 / +1.83 (+2.32%) 05/26/20 Merck CEO: 12-18 month COVID vaccine timeline 'very aggressive,' FT reports 05/22/20 U.S. plans 'massive' vaccine testing with over 100,000 patients, Reuters says BMY Bristol-Myers $59.72 / -0.08 (-0.13%) 02/01/20 Oracle, Discovery still looking cheap, Barron's says 01/03/20 Novartis, Merck, Allergan raise U.S. prices on over 100 drugs, Reuters reports 12/13/19 Bristol-Myers awarded $585M in damages in patent win over Gilead, Bloomberg says 12/13/19 Bristol-Myers awarded $585M in damages in patent win over Gilead, Bloomberg says AZN AstraZeneca $54.60 / +1.1 (+2.06%) 05/29/20 AstraZeneca may consider exposing trial participants to virus, Reuters reports 05/27/20 AstraZeneca tests Farxiga as COVID-19 treatment, Reuters reports 05/22/20 U.S. plans 'massive' vaccine testing with over 100,000 patients, Reuters says 05/22/20 Astra-Oxford vaccine may be tested 'side-by-side' with Moderna's, Reuters says AMGN Amgen $230.13 / +6.11 (+2.73%) 05/28/20 Elliott says Alexion settlement may 'leave the door open' for strategic review 03/06/20 Roche bid to block Amgen's Herceptin biosimilar fails, Bloomberg reports 01/07/20 Amgen wins ruling that Amneal's Zydus infringes Sensipar patent, Bloomberg says ABBV AbbVie $92.78 / +2.77 (+3.08%) 03/23/20 AbbVie gives up patent rights for Keltra antiviral treatment, FT reports 03/19/20 AbbVie's Kaletra fails as treatment for severe COVID-19, Reuters reports 03/07/20 J&J, Amgen among healthy dividend stocks as COVID-19 fears grow, Barron's says 03/07/20 AT&T, Dow among dividend stocks to buy amid coronavirus selloff, Barron's says XNCR STML SGEN SBPH PFE MRSN MRK KPTI HALO EXEL DCPH BPMC BMY BLUE BCYC AZN AVEO ATNX AMGN ALLO ABBV XNCR Xencor $30.30 / -0.69 (-2.23%) 05/07/20 Fly Intel: After-Hours Movers STML Stemline $11.89 / + (+0.00%) 05/04/20 Fly Intel: Wall Street's top stories for Monday 05/04/20 Fly Intel: Wall Street's top stories at midday 05/04/20 Fly Intel: Pre-market Movers SGEN Seattle Genetics $157.30 / +5.53 (+3.64%) 05/01/20 Fly Intel: Gilead, Beyond Meat downgrades among today's top calls on Wall Street 04/30/20 Fly Intel: After-Hours Movers SBPH Spring Bank Pharmaceuticals $1.66 / +0.015 (+0.91%) 12/30/19 Bullish takes on Chipotle, Crowdstrike among today's top Wall Street calls 12/27/19 Downgrades of Spring Bank, Darden among today's top analyst calls 12/26/19 Fly Intel: Wall Street's top stories for Thursday 12/26/19 Fly Intel: Wall Street's top stories at midday PFE Pfizer $38.14 / -0.03 (-0.08%) 05/15/20 Fly Intel: Wall Street's top stories for Friday 05/15/20 Sarepta jumps after Pfizer announces DMD gene therapy data 05/05/20 Fly Intel: Wall Street's top stories for Tuesday 05/05/20 Fly Intel: Wall Street's top stories at midday MRSN Mersana Therapeutics $22.55 / +2.85 (+14.47%) 05/27/20 Fly Intel: Wall Street's top stories for Wednesday 04/13/20 Fly Insider: Carnival, SBA among week's notable insider transactions MRK Merck $80.85 / +1.83 (+2.32%) 05/26/20 Fly Intel: Wall Street's top stories for Tuesday 05/26/20 Fly Intel: Wall Street's top stories at midday 05/26/20 Fly Intel: Pre-market Movers KPTI Karyopharm $18.49 / -0.31 (-1.65%) 05/28/20 Fly Intel: After-Hours Movers 05/05/20 Fly Intel: Pre-market Movers 03/03/20 Fly Intel: Pre-market Movers HALO Halozyme $24.26 / +0.79 (+3.37%) 05/11/20 Fly Intel: After-Hours Movers EXEL Exelixis $24.68 / +0.35 (+1.44%) 04/20/20 Fly Intel: Wall Street's top stories for Monday 04/20/20 Fly Intel: Wall Street's top stories at midday 04/20/20 Fly Intel: Pre-market Movers DCPH Deciphera $58.47 / +1.53 (+2.69%) 03/12/20 Before the Move: Watch Blueprint Medicines into Phase 2 trial update BPMC Blueprint Medicines $65.16 / -1.84 (-2.75%) 04/28/20 Fly Intel: Wall Street's top stories for Tuesday 04/28/20 Fly Intel: Wall Street's top stories at midday 04/28/20 Fly Intel: Pre-market Movers BMY Bristol-Myers $59.72 / -0.08 (-0.13%) 05/26/20 Fly Intel: After-Hours Movers 05/07/20 Fly Intel: Pre-market Movers 05/06/20 Novo Nordisk slips as analysts discuss NASH data, read-through to peers BLUE Bluebird Bio $63.63 / +2.82 (+4.64%) 05/18/20 Fly Intel: Pre-market Movers 05/13/20 Fly Intel: Pre-market Movers BCYC Bicycle Therapeutics $17.50 / -0.785 (-4.29%) 03/10/20 Fly Intel: Pre-market Movers AZN AstraZeneca $54.60 / +1.1 (+2.06%) 05/23/20 Week in Review: How Trump's policies moved stocks 03/24/20 Innate rises again on potential use of cancer drug against COVID-19 03/02/20 Larger coronavirus drag on U.S. growth seen as analysts discuss further impact 01/13/20 Amarin jumps after AstraZeneca fish oil drug trial fails AVEO Aveo Pharmaceuticals $8.14 / -1.08 (-11.71%) 05/29/20 Fly Intel: Pre-market Movers 03/31/20 Fly Intel: After-Hours Movers ATNX Athenex $10.91 / -0.21 (-1.89%) 12/30/19 Fly Insider: Kodak, Quotient among week's notable insider trades 12/13/19 Fly Intel: Wall Street's top stories for Friday 12/13/19 Fly Intel: Wall Street's top stories at midday AMGN Amgen $230.13 / +6.11 (+2.73%) 05/28/20 Alexion rises as documents suggest settlement of Amgen patent challenge 05/28/20 Fly Intel: Pre-market Movers 03/30/20 Fly Intel: Alphabet upgrade among today's top calls on Wall Street 03/12/20 Piper sees trial disruption risk, calls out Moderna, Inovio as 'COVID-19 plays' ALLO Allogene Therapeutics $48.08 / +1.48 (+3.18%) 05/14/20 Fly Intel: Wall Street's top stories for Thursday 05/14/20 Allogene jumps, Compugen plunges following release of cancer meeting abstracts 05/14/20 Fly Intel: Pre-market Movers 05/13/20 Fly Intel: After-Hours Movers ABBV AbbVie $92.78 / +2.77 (+3.08%) 05/12/20 CarMax upgrade, Chevron downgrade among today's top calls on Wall Street 03/20/20 Inovio, Moderna gain ahead of Sunday's 60 Minutes report on COVID-19 vaccines 03/18/20 COVID-19 drug seen as possible this year, vaccine in 2021 as crisis continues 02/07/20 Fly Intel: Wall Street's top stories for Friday 07/31/20 Merck - MRK 06/04/20 PDUFA Date for RECARBRIO 06/16/20 PDUFA Date for KEYTRUDA 06/23/20 PDUFA Date for Oral XPOVIO (Selinexor) Tablets 08/06/20 PDUFA Date for CM-9LA Opdivo + Yervoy 08/13/20 PDUFA Date for Ripretinib 08/17/20 PDUFA Date for Lisocabtagene Maraleucel (liso-cel) 08/20/20 PDUFA Date for Tucantinib 09/03/20 PDUFA Date for CC-486 11/15/20 PDUFA Date 12/30/20 PDUFA Date for Tirbanibulin Ointment 06/01/20 Compugen 06/05/20 Athenex, Inc. 06/05/20 Allogene Therapeutics, Inc. 06/10/20 Deciphera Pharmaceuticals, Inc. 06/10/20 AVEO Pharmaceuticals, Inc. 06/11/20 NextCure, Inc. 06/11/20 Syros Pharmaceuticals, Inc. 06/12/20 Mersana Therapeutics, Inc. 06/18/20 bluebird bio, Inc. 06/23/20 Blueprint Medicines Corp. 06/24/20 Spring Bank Pharmaceuticals, Inc. 06/24/20 Kura Oncology, Inc. 06/25/20 Xencor, Inc. 06/30/20 Trillium Therapeutics Inc. TRIL RECN PFE MRSN MRK EXEL BMY AZN ABBV TRIL Trillium Therapeutics $6.76 / +0.995 (+17.26%) 05/05/20 Largest borrow rate increases among liquid names 04/03/20 Largest borrow rate increases among liquid names 02/11/20 Largest borrow rate increases among liquid names 02/05/20 Largest borrow rate increases among liquid names RECN Changed to RGP $0.00 / + (+0.00%) 04/02/20 Three new option listings and four option delistings on April 2nd PFE Pfizer $38.14 / -0.03 (-0.08%) 05/05/20 Unusually active option classes on open May 5th 04/28/20 Unusually active option classes on open April 28th 04/06/20 Unusual call flow in option market yesterday 04/03/20 Opening call sale in Pfizer struck 7.4% above spot MRSN Mersana Therapeutics $22.55 / +2.85 (+14.47%) 02/12/20 Four new option listings and one option delisting on February 12th MRK Merck $80.85 / +1.83 (+2.32%) 05/14/20 Early notable gainers among liquid option names on May 14th 04/09/20 Merck call volume above normal and directionally bullish 02/05/20 Unusually active option classes on open February 5th EXEL Exelixis $24.68 / +0.35 (+1.44%) 05/11/20 Exelixis call volume above normal and directionally bullish 05/08/20 Exelixis call volume above normal and directionally bullish 03/06/20 Exelixis call volume above normal and directionally bullish 02/18/20 Exelixis put volume heavy and directionally bearish BMY Bristol-Myers $59.72 / -0.08 (-0.13%) 05/01/20 Bristol Myers Squibb put volume heavy and directionally bearish 04/20/20 Bristol Myers Squibb call volume above normal and directionally bullish 04/20/20 Early notable gainers among liquid option names on April 20th 03/30/20 Unusually active option classes on open March 30th AZN AstraZeneca $54.60 / +1.1 (+2.06%) 05/28/20 Unusually active option classes on open May 28th 05/27/20 AstraZeneca call volume above normal and directionally bullish 05/22/20 Unusually active option classes on open May 22nd ABBV AbbVie $92.78 / +2.77 (+3.08%) 05/19/20 Unusually active option classes on open May 19th 05/12/20 Early notable gainers among liquid option names on May 12th 05/12/20 Unusually active option classes on open May 12th 02/07/20 Early notable gainers among liquid option names on February 7th
Conference/Events	American Society of Clinical Oncology (ASCO) to hold virtual meeting » 10:14 05/29/20 05/29 10:14 05/29/20 10:14 ABBV AbbVie $90.97 / +0.96 (+1.07%) , ALLO Allogene Therapeutics $45.80 / -0.8 (-1.72%) , AMGN Amgen $224.10 / +0.08 (+0.04%) , ATNX Athenex $11.08 / -0.04 (-0.36%) , AVEO Aveo Pharmaceuticals $8.01 / -1.21 (-13.12%) , AZN AstraZeneca $54.97 / +1.47 (+2.75%) , BCYC Bicycle Therapeutics $18.28 / + (+0.00%) , BLUE Bluebird Bio $61.30 / +0.49 (+0.81%) , BPMC Blueprint Medicines $66.44 / -0.56 (-0.84%) , CGEN Compugen $12.92 / +0.55 (+4.45%) , HALO Halozyme $23.49 / +0.02 (+0.09%) , EXEL Exelixis $24.46 / +0.13 (+0.53%) , DCPH Deciphera $56.95 / +0.01 (+0.02%) , KURA Kura Oncology $17.10 / +0.39 (+2.33%) , KPTI Karyopharm $18.80 / + (+0.00%) , MRK Merck $79.24 / +0.22 (+0.28%) , BMY Bristol-Myers $60.18 / +0.38 (+0.64%) , MRSN Mersana Therapeutics $20.50 / +0.8 (+4.06%) , NXTC NextCure $32.56 / -0.6 (-1.81%) , PFE Pfizer $38.06 / -0.11 (-0.29%) , RECN Changed to RGP $0.00 / + (+0.00%) , REPL Replimune Group $18.41 / -0.14 (-0.75%) , SBPH Spring Bank Pharmaceuticals $1.56 / -0.085 (-5.17%) , SGEN Seattle Genetics $154.34 / +2.57 (+1.69%) , STML Stemline $11.88 / -0.01 (-0.08%) , SYRS Syros Pharmaceuticals $9.43 / -0.09 (-0.95%) , TRIL Trillium Therapeutics $6.20 / +0.435 (+7.55%) , TROV Changed name to CRDF $0.00 / + (+0.00%) , XNCR Xencor $30.45 / -0.54 (-1.74%) Virtual Annual Meeting of… Virtual Annual Meeting of ASCO 2020 will be held on May 29-31. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options XNCR TROV TRIL SYRS STML SGEN SBPH REPL RECN PFE NXTC MRSN MRK KURA KPTI HALO EXEL DCPH CGEN BPMC BMY BLUE BCYC AZN AVEO ATNX AMGN ALLO ABBV XNCR Xencor $30.45 / -0.54 (-1.74%) 05/13/20 Xencor reports initial dose escalation in ph1 study of XmAb20717 03/25/20 Xencor, Vir Biotechnology enter license agreement for use of Xtend in Covid-19 03/24/20 Exagen appoints Debra Jeske Zack as CMO, Anja Kammesheidt as CSO 02/05/20 Aimmune obtains license for XmAb7195 from Xencor for $5M in cash, $5M in equity TROV Changed name to CRDF $0.00 / + (+0.00%) 05/06/20 Trovagene changing company name to Cardiff Oncology, appoints Mark Erlander CEO 04/28/20 Trovagene announces results from Phase 1b/2 clinical trial of onvansertib 02/13/20 Trovagene presents Phase 2 efficacy data on onvansertib for mCRPC 01/29/20 Trovagene receives approximately $1.45M from exercise of warrants TRIL Trillium Therapeutics $6.20 / +0.435 (+7.55%) 05/29/20 Trillium updates dose escalation sudy of CD47 Blocker TTI-622 at ASCO 05/06/20 Trillium Therapeutics announces ATM equity program 04/08/20 Trillium Therapeutics says difficult to predict COVID-19 impact 04/08/20 Trillium Therapeutics says cash runway 'sufficient' into 2022 SYRS Syros Pharmaceuticals $9.43 / -0.09 (-0.95%) 05/29/20 Syros Pharmaceuticals presents new preclinical data for SY-5609 at ASCO 04/02/20 Point72 discloses 5.1% passive stake in Syros Pharmaceuticals 01/29/20 Syros Pharmaceuticals announces preclinical data on CDK7, CDK12 01/28/20 Syros Pharmaceuticals doses first patient in SY-5609 Phase 1 clinical trial STML Stemline $11.88 / -0.01 (-0.08%) 05/04/20 Stemline trading resumes 05/04/20 Menarini Group to acquire Stemline in transaction valued at up to $677M 05/04/20 Stemline trading halted, news pending 01/13/20 Fly Intel: After Hours Movers SGEN Seattle Genetics $154.34 / +2.57 (+1.69%) 05/29/20 Seattle Genetics announces results from exploratory analyses of HER2CLIMB trial 05/14/20 Takeda Pharmaceutical receives EC approval for Adcetris MA extension 05/12/20 Seattle Genetics Tukysa receives Swiss Agency for Therapeutic Products approval 04/30/20 Seattle Genetics sees FY20 ADCETRIS net product sales $675M-$700M SBPH Spring Bank Pharmaceuticals $1.56 / -0.085 (-5.17%) 04/02/20 Spring Bank Pharmaceuticals continues trial for IB SB 11285 04/02/20 Spring Bank says safety committee for SB 11285 trial recommends dose escalation 02/25/20 Spring Bank, Roche announces collaboration to evaluate SB 11285 w/ atezolizumab 01/29/20 Spring Bank down 4.5% after discontinuing development of inarigivir soproxil REPL Replimune Group $18.41 / -0.14 (-0.75%) 04/02/20 Replimune Group appoints Dieter Weinand as chairman of the board 02/13/20 Replimune Group 'on track' to initiate Phase 1 trial of RP3 in 2020 02/13/20 Replimune Group expects inital data from Phase 1 trial of RP2 by end of 2020 02/13/20 Replimune Group 'on track' to initiate Phase 1/2 trial of RP1 in 1H20 RECN Changed to RGP $0.00 / + (+0.00%) 03/30/20 Resources Connection to change trading symbol to 'RGP' 02/04/20 Resources Connection names Jennifer Ryu as new CFO 01/03/20 Resources Connections rises after upbeat Q2 earnings 01/02/20 Fly Intel: After Hours Movers PFE Pfizer $38.06 / -0.11 (-0.29%) 05/29/20 Pfizer, Astellas Pharma: PROSPER results show XTANDI 'signifcantly extends' OS 05/28/20 Corning, Pfizer announce supply agreement for Corning Valor Glass Packaging 05/26/20 ContraFect announces stock purchase agreement with Pfizer 05/22/20 Multiple COVID-19 vaccine trials underway with multiple candidates, Fauci says NXTC NextCure $32.56 / -0.6 (-1.81%) 05/29/20 NextCure presents biomarker data, results form NC318 trial at ASCO 04/13/20 NextCure temporarily delays start of NC410 Phase 1/2 trial 04/13/20 NextCure expects data from Phase 2 of Phase 1/2 NC318 trial to be delayed 04/13/20 NextCure temporarily delays start of NC318 combination clinical trial MRSN Mersana Therapeutics $20.50 / +0.8 (+4.06%) 05/27/20 Mersana Therapeutics reports interim Phase 1 data for XMT-1536 cancer candidate 05/14/20 Mersana Therapeutics initiates patient dosing in XMT-1592 dose escalation study 05/13/20 Mersana Therapeutics to report interim data from Phase 1 dose expansion of XMT-1 04/15/20 Mersana Therapeutics appoints Martin Huber to board of directors MRK Merck $79.24 / +0.22 (+0.28%) 05/28/20 Merck, Eisai announce new data from KEYTRUDA plus LENVIMA trials 05/28/20 Merck study shows KEYTRUDA reduced risk of progression, death by 40% 05/26/20 Merck jumps 2.5% in premarket trading on plans for COVID-19 vaccines, treatment 05/26/20 Merck, Ridgeback Bio collaborate to advance development of EIDD-2801 KURA Kura Oncology $17.10 / +0.39 (+2.33%) 05/29/20 Kura reports data from tipifarnib study of metastatic HRAS mutant HNSCC 03/03/20 Kura Oncology receives Fast Track designation for tipifarnib in T-cell lymphomas 01/23/20 Kura Oncology appoints Bridget Martell acting Chief Medical Officer 01/06/20 Kura Oncology appoints Kirsten Flowers as CCO KPTI Karyopharm $18.80 / + (+0.00%) 05/28/20 Karyopharm reports Phase 3 Boston data in ASCO presentation 05/20/20 Karyopharm submits sNDA to FDA for XPOVIO 05/13/20 Karyopharm donates 60,000 medical masks across Massachusetts, the U.S. 05/05/20 Antengene broadens partnership with Karyopharm HALO Halozyme $23.49 / +0.02 (+0.09%) 05/14/20 Halozyme to receive $15M milestone payment from Johnson & Johnson's Janssen 05/01/20 Halozyme announces FDA approval of DARZALEX FASPRO for Janssen Biotech 04/30/20 Halozyme discloses Janssen receipt CHMP positive opinion for Darzalex 04/27/20 Halozyme announces daratumumab NDA filed in Japan by Janssen EXEL Exelixis $24.46 / +0.13 (+0.53%) 05/13/20 Exelixis to present ph. 1b trial results for cabozantinib+atezolizumab as ASCO 04/20/20 Bristol-Myers, Exelixis: CheckMate-9ER met primary endpoint of PFS 03/25/20 Exelixis says Takeda Pharmaceutical receives approval in Japan for CABOMETYX 02/25/20 Fly Intel: After Hours Movers DCPH Deciphera $56.95 / +0.01 (+0.02%) 05/29/20 Deciphera presents results from INVICTUS pivotal Phase 3 study at ASCO 05/29/20 Deciphera presents data from cohort of Part 2 of rebastinib Phase 1b/2 at ASCO 05/15/20 Deciphera announces FDA approval of QINLOCK for treatment of GIST 05/15/20 Deciphera up over 5% after receiving FDA approval for ripretinib in 4L+GIST CGEN Compugen $12.92 / +0.55 (+4.45%) 05/27/20 Compugen doses first patient in COM701 Phase 1 monotherapy expansion cohort 04/22/20 Compugen granted patent in Europe for backup cancer antibodies 04/20/20 Compugen and Bayer's BAY 1905254 study results published in reviewed paper 04/06/20 Compugen: First patient dosed in COM902 Phase 1 trial BPMC Blueprint Medicines $66.44 / -0.56 (-0.84%) 05/29/20 Blueprint Medicines presents data from ARROW clinical trial of pralsetinib 05/15/20 Blueprint Medicines receives CRL from FDA on NDA for avapritinib 05/06/20 Blueprint Medicines: Cash sufficient to fund operating expenses to 2H22 04/28/20 Blueprint Medicines trading resumes BMY Bristol-Myers $60.18 / +0.38 (+0.64%) 05/29/20 Heat Biologics presents HS-110/Opdivo combination Phase 2 trial data at ASCO 05/28/20 WindMIL doses first patient in Phase 2 study of MILs in combo w/ nivolumab 05/27/20 TCR2 Therapeutics appoints Gregg McConnell as head of business development BLUE Bluebird Bio $61.30 / +0.49 (+0.81%) 05/29/20 Bristol-Myers CEO says 'very much on track' with ide-cel resubmission 05/13/20 Bluebird Bio, Bristol-Myers to update results from KarMMa Study of Ide-cel 05/13/20 Bluebird sinks after FDA issues Refusal to File letter for myeloma treatment 05/13/20 Bristol-Myers, Bluebird Bio receive RTF letter on BLA for idecabtagene vicleucel BCYC Bicycle Therapeutics $18.28 / + (+0.00%) 05/05/20 Bicycle announces dosing of first patient in Phase I study of BT5528 04/07/20 Bicycle Therapeutics expects to reach 2020 milestones as planned 03/12/20 Bicycle Therapeutics PLC (ADS) trading resumes 03/12/20 Bicycle Therapeutics PLC (ADS) trading halted, volatility trading pause AZN AstraZeneca $54.97 / +1.47 (+2.75%) 05/29/20 AstraZeneca reports results from updated CASPIAN trial analysis 05/29/20 AstraZeneca says Imfinzi showed sustained overall survival benefit 05/29/20 AstraZeneca announces results from Imfinzi plus tremelimumab trial 05/29/20 AstraZeneca says Enhertu improved overall survival in gastric cancer trial AVEO Aveo Pharmaceuticals $8.01 / -1.21 (-13.12%) 05/29/20 Aveo Pharmaceuticals DEDUCTIVE trial advances to Phase 2 portion 05/29/20 Aveo presents results from final analysis of Phase 3 TIVO-3 trial 03/31/20 Aveo submits NDA to FDA for tivozanib 03/27/20 Aveo Oncology discontinues CyFi-2 study due to impact of COVID-19 ATNX Athenex $11.08 / -0.04 (-0.36%) 05/29/20 Athenex presents interim data from oral paclitaxel Phase II study 05/07/20 Athenex sees 2020 y-o-y product sales growth in mid-single digits 05/07/20 Athenex announces upcoming milestones 05/07/20 Athenex expects cash, cash equivalents to fund operations into 1Q21 AMGN Amgen $224.10 / +0.08 (+0.04%) 05/29/20 Amgen presents new AMG 510 clinical data 05/08/20 Cytokinetics, Amgen granted Fast Track designation for omecamtiv mecarbil 05/08/20 Amgen,Cytokinetics: FDA grants Fast Track designation for omecamtiv mecarbil 05/06/20 Amgen reports 'positive' results from Otezla Phase 3 ADVANCE study ALLO Allogene Therapeutics $45.80 / -0.8 (-1.72%) 05/29/20 Allogene Therapeutics reports results from Phase 1 ALPHA study of ALLO-501 05/26/20 Allogene Therapeutics announces webinar to review initial ALLO-501 phase 1 data 05/13/20 Allogene Therapeutics jumps 32% after reporting ALLO-501 data 05/06/20 Allogene Therapeutics expects 2020 net losses $260M-$280M ABBV AbbVie $90.97 / +0.96 (+1.07%) 05/27/20 Ironwood, AbbVie announce MD-7246 trial did not meet primary endpoint 05/21/20 Synlogic announces termination of IBD treatment collaboration with AbbVie 05/12/20 AbbVie director sells 23K shares of common stock 05/08/20 Abbvie completes Allergan acquisition, sees combined FY20 revenue of about $50B ABBV ALLO AMGN ATNX AVEO AZN BCYC BLUE BPMC CGEN HALO EXEL DCPH KURA KPTI MRK BMY MRSN NXTC PFE RECN REPL SBPH SGEN STML SYRS TRIL TROV XNCR ABBV AbbVie $90.97 / +0.96 (+1.07%) 05/22/20 Piper Sandler Growth of Biohaven's Nurtec continues to beat AbbVie's Ubrelvy, says Piper 05/21/20 Piper Sandler Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration 05/18/20 BofA AbbVie reinstated with a Neutral at BofA 05/12/20 JPMorgan AbbVie resumed with an Overweight from Neutral at JPMorgan ALLO Allogene Therapeutics $45.80 / -0.8 (-1.72%) 05/19/20 Roth Capital Allogene Therapeutics upgraded to Buy with $60 target at Roth Capital 05/19/20 Roth Capital Allogene Therapeutics upgraded to Buy from Neutral at Roth Capital 05/18/20 H.C. Wainwright Precision BioSciences could have 'significant upside,' says H.C. Wainwright 05/15/20 Guggenheim Guggenheim upgrades Allogene to Buy with $50 target after ASCO upside surprise AMGN Amgen $224.10 / +0.08 (+0.04%) 05/28/20 Piper Sandler Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler 05/28/20 Cowen Alexion settlement may yield upside surprise, says Cowen 05/28/20 Stifel Alexion, Amgen appear to have agreed to settlement deal, says Stifel 05/22/20 Piper Sandler Harpoon Therapeutics initiated with an Overweight at Piper Sandler ATNX Athenex $11.08 / -0.04 (-0.36%) 12/13/19 RBC Capital Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital 12/06/19 Truist Athenex initiated with a Buy at SunTrust 11/19/19 RBC Capital Athenex gets 'third SABCS win' ahead of meeting, says RBC Capital 08/07/19 RBC Capital Athenex's Oraxol data 'near best-case,' says RBC Capital AVEO Aveo Pharmaceuticals $8.01 / -1.21 (-13.12%) 05/29/20 Baird Aveo Pharmaceuticals price target raised to $24 from $15 at Baird 05/01/20 H.C. Wainwright Aveo Pharmaceuticals price target raised to $10 from $6 at H.C. Wainwright 04/01/20 H.C. Wainwright Aveo Pharmaceuticals price target raised to $6 from $4 at H.C. Wainwright 03/31/20 Piper Sandler Aveo Pharmaceuticals price target lowered to $18.50 from $20 at Piper Sandler AZN AstraZeneca $54.97 / +1.47 (+2.75%) 05/29/20 Guggenheim AstraZeneca price target raised to 10,100 GBp from 9,100 GBp at Guggenheim 05/14/20 Evercore ISI Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine 05/06/20 Morgan Stanley AstraZeneca price target raised to 8,630 GBp from 8,600 GBp at Morgan Stanley 05/04/20 Citi Citi opens 'positive catalyst watch' on AstraZeneca BCYC Bicycle Therapeutics $18.28 / + (+0.00%) 04/17/20 Fly Intel: Top five analyst initiations 04/17/20 H.C. Wainwright Bicycle Therapeutics initiated with a Buy at H.C. Wainwright 04/07/20 Piper Sandler Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler 02/25/20 Piper Sandler Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler BLUE Bluebird Bio $61.30 / +0.49 (+0.81%) 05/13/20 Stifel Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel 05/13/20 Piper Sandler Bluebird should be able to easily address RTF issues, says Piper Sandler 05/12/20 RBC Capital Bluebird Bio initiated with an Outperform at RBC Capital 05/12/20 Oppenheimer Bluebird Bio price target lowered to $111 from $122 at Oppenheimer BPMC Blueprint Medicines $66.44 / -0.56 (-0.84%) 05/06/20 Nomura Instinet Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet 05/05/20 Barclays Blueprint Medicines initiated with an Equal Weight at Barclays 04/29/20 SVB Leerink Deciphera price target raised to $55 from $50 at SVB Leerink 04/29/20 SVB Leerink Blueprint Medicines price target lowered to $105 from $125 at SVB Leerink CGEN Compugen $12.92 / +0.55 (+4.45%) 05/26/20 JMP Securities Compugen resumed with an Outperform at JMP Securities 05/13/20 Fly Intel: Top five analyst initiations 05/13/20 Stifel Compugen initiated with a Buy at Stifel 05/07/20 Fly Intel: Top five analyst initiations HALO Halozyme $23.49 / +0.02 (+0.09%) 05/26/20 Piper Sandler Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler 05/12/20 JMP Securities Halozyme price target raised to $34 from $24 at JMP Securities 05/04/20 Cantor Fitzgerald Halozyme price target raised to $39 from $35 at Cantor Fitzgerald 03/23/20 Citi Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak EXEL Exelixis $24.46 / +0.13 (+0.53%) 05/14/20 Truist Exelixis price target raised to $40 from $35 at SunTrust 05/13/20 Piper Sandler Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler 05/06/20 Piper Sandler Exelixis price target raised to $30 from $23 at Piper Sandler 04/21/20 Guggenheim Exelixis price target raised to $32 from $27 at Guggenheim DCPH Deciphera $56.95 / +0.01 (+0.02%) 05/18/20 Truist Deciphera price target raised to $91 from $82 at SunTrust 05/18/20 Barclays Deciphera price target raised to $85 from $80 at Barclays 05/18/20 Piper Sandler Piper Sandler a buyer of Deciphera shares on the open 05/15/20 Piper Sandler Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler KURA Kura Oncology $17.10 / +0.39 (+2.33%) 05/19/20 Deutsche Bank Kura Oncology price target lowered to $24 from $28 at Deutsche Bank 05/06/20 Wedbush Kura prioritizing development of tipifarnib for HRAS-HNSCC, says Wedbush 05/05/20 H.C. Wainwright Kura Oncology price target lowered to $22 from $29 at H.C. Wainwright 05/05/20 Barclays Kura Oncology initiated with an Overweight at Barclays KPTI Karyopharm $18.80 / + (+0.00%) 05/06/20 H.C. Wainwright Karyopharm price target lowered to $40 from $43 at H.C. Wainwright 04/07/20 Wedbush Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID 04/07/20 H.C. Wainwright XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright 03/04/20 Barclays Karyopharm initiated with an Overweight at Barclays MRK Merck $79.24 / +0.22 (+0.28%) 05/27/20 Alliance Global Partners PDS Biotechnology initiated with a Buy at Alliance Global Partners 05/20/20 JonesTrading Merck collaboration positions Surface Oncology well, says JonesTrading 04/27/20 SVB Leerink Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades 04/06/20 Raymond James NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James BMY Bristol-Myers $60.18 / +0.38 (+0.64%) 04/20/20 Piper Sandler Exelixis combo approval would increase kidney cancer use, says Piper Sandler MRSN Mersana Therapeutics $20.50 / +0.8 (+4.06%) 05/27/20 H.C. Wainwright Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright 04/29/20 BTIG Mersana Therapeutics initiated with a Buy at BTIG 01/21/20 H.C. Wainwright Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright 08/20/19 H.C. Wainwright H.C. Wainwright says trial initiation at higher dosing 'bodes well' for Mersana NXTC NextCure $32.56 / -0.6 (-1.81%) 05/26/20 JMP Securities NextCure initiated with an Outperform at JMP Securities 04/13/20 Piper Sandler NextCure could report Phase I biomarker data at ASCO, says Piper Sandler 03/24/20 Benchmark NextCure initiated with a Buy at Benchmark 03/02/20 Roth Capital NextCure initiated with a Buy at Roth Capital PFE Pfizer $38.06 / -0.11 (-0.29%) 05/21/20 Piper Sandler Gilead's filgotinib likely being underestimated by Street, says Piper Sandler 05/19/20 H.C. Wainwright BioNTech upgraded to Buy from Neutral at H.C. Wainwright 05/15/20 Goldman Sachs After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy 05/15/20 JPMorgan JPMorgan still sees Sarepta in pole position in DMD space RECN Changed to RGP $0.00 / + (+0.00%) 01/03/20 Baird Resources Connection Q3 guidance 'materially below' expectations, says Baird 10/03/19 JPMorgan Resources Connection near-term outlook remains challenged, says JPMorgan REPL Replimune Group $18.41 / -0.14 (-0.75%) 05/05/20 Barclays Replimune Group initiated with an Overweight at Barclays 03/25/20 Wedbush Replimune Group added to Best Ideas List at Wedbush 11/11/19 Roth Capital Replimune Group price target raised to $30 from $20 at Roth Capital 09/04/19 Roth Capital Replimune Group initiated with a Buy at Roth Capital SBPH Spring Bank Pharmaceuticals $1.56 / -0.085 (-5.17%) 04/02/20 Piper Sandler Piper Sandler keeps Neutral on Spring Bank as study enrollment expected to slow 01/29/20 Jefferies Spring Bank Pharmaceuticals downgraded to Hold from Buy at Jefferies 01/29/20 Piper Sandler Piper keeps Neutral rating on Spring Bank after inarigivir discontinued 12/30/19 Fly Intel: Top five analyst actions SGEN Seattle Genetics $154.34 / +2.57 (+1.69%) 05/26/20 Goldman Sachs Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs 05/26/20 JMP Securities Seattle Genetics initiated with an Outperform at JMP Securities 05/26/20 Goldman Sachs Incyte downgraded to Buy from Conviction Buy at Goldman Sachs 05/26/20 Goldman Sachs Seattle Genetics upgraded to Conviction Buy from Buy at Goldman Sachs STML Stemline $11.88 / -0.01 (-0.08%) 05/05/20 H.C. Wainwright Stemline downgraded to Neutral from Buy at H.C. Wainwright 05/05/20 Ladenburg Stemline downgraded to Neutral from Buy at Ladenburg 05/04/20 Alliance Global Partners Stemline downgraded to Neutral from Buy at Alliance Global Partners 05/04/20 Wedbush Stemline downgraded to Neutral from Outperform at Wedbush SYRS Syros Pharmaceuticals $9.43 / -0.09 (-0.95%) 04/23/20 JonesTrading Syros Pharmaceuticals initiated with a Buy at JonesTrading 03/06/20 H.C. Wainwright Syros Pharmaceuticals price target lowered to $8 from $10 at H.C. Wainwright 01/17/20 Wedbush Syros Pharmaceuticals risk/reward balanced ahead of data readouts, says Wedbush 01/17/20 Wedbush Syros Pharmaceuticals downgraded to Neutral from Outperform at Wedbush TRIL Trillium Therapeutics $6.20 / +0.435 (+7.55%) 05/26/20 JMP Securities Trillium Therapeutics initiated with an Outperform at JMP Securities 08/19/19 Fly Intel: Top five analyst downgrades 08/19/19 H.C. Wainwright Trillium Therapeutics downgraded to Neutral from Buy at H.C. Wainwright TROV Changed name to CRDF $0.00 / + (+0.00%) 01/28/20 Noble Capital Trovagene resumed with an Outperform at Noble Capital XNCR Xencor $30.45 / -0.54 (-1.74%) 05/13/20 Piper Sandler Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler 03/04/20 Barclays Barclays starts small, mid cap Biotechnology sector with Positive view 03/04/20 Barclays Xencor initiated with an Underweight at Barclays 02/25/20 Guggenheim Xencor upgraded to Buy from Neutral at Guggenheim XNCR TRIL SYRS STML SGEN SBPH REPL RECN PFE NXTC MRSN MRK KURA KPTI HALO EXEL DCPH CGEN BPMC BMY BLUE BCYC AZN AVEO ATNX AMGN ALLO ABBV XNCR Xencor $30.45 / -0.54 (-1.74%) 05/07/20 Xencor reports Q1 EPS (14c), consensus (38c) 02/24/20 Xencor sees ending 2020 with $500M-$550M in cash 02/24/20 Xencor reports Q4 EPS (47c), consensus (41c) TRIL Trillium Therapeutics $6.20 / +0.435 (+7.55%) 05/15/20 Trillium Therapeutics reports Q1 EPS ($1.07), consensus (90c) 03/10/20 Trillium Therapeutics reports FY19 EPS ($1.65) vs. ($2.35) last year SYRS Syros Pharmaceuticals $9.43 / -0.09 (-0.95%) 05/13/20 Syros Pharmaceuticals director Mark Alles bought 10K shares of company stock 05/07/20 Syros Pharmaceuticals reports Q1 EPS (39c), consensus (43c) 03/05/20 Syros Pharmaceuticals reports Q4 EPS (46c), consensus (47c) STML Stemline $11.88 / -0.01 (-0.08%) 03/13/20 Stemline Therapeutics reports Q4 EPS (38c), consensus (35c) SGEN Seattle Genetics $154.34 / +2.57 (+1.69%) 04/30/20 Seattle Genetics reports Q1 EPS (98c), consensus (79c) 02/06/20 Seattle Genetics sees 2020 Adcetris net sales $675M-$700M 02/06/20 Seattle Genetics reports Q4 EPS 14c, consensus (45c) 02/06/20 Notable companies reporting after market close SBPH Spring Bank Pharmaceuticals $1.56 / -0.085 (-5.17%) 02/14/20 Spring Bank Pharmaceuticals reports Q4 EPS (45c), consensus (67c) REPL Replimune Group $18.41 / -0.14 (-0.75%) 02/13/20 Replimune Group reports Q3 EPS (46c), consensus (36c) RECN Changed to RGP $0.00 / + (+0.00%) 04/02/20 Resources Connection sees $4M-$5M charge from restructuring initiative 04/02/20 Resources Connection reports Q3 EPS 21c, two estimates 11c 01/02/20 Resources Connection reports Q2 EPS 38c, consensus 30c PFE Pfizer $38.06 / -0.11 (-0.29%) 05/10/20 Fly Intel: Top five weekend stock stories 04/28/20 Pfizer backs FY20 adjusted EPS view $2.82-$2.92, consensus $2.86 04/28/20 Pfizer reaffirms FY20 guidance for adjusted EPS, revenue 04/28/20 Pfizer reports Q1 adjusted EPS 80c, consensus 73c NXTC NextCure $32.56 / -0.6 (-1.81%) 05/07/20 NextCure reports Q1 EPS 35c, consensus (44c) MRSN Mersana Therapeutics $20.50 / +0.8 (+4.06%) 05/08/20 Mersana Therapeutics reports Q1 EPS (35c), consensus (37c) 02/28/20 Mersana Therapeutics reports Q4 EPS (34c), consensus (38c) MRK Merck $79.24 / +0.22 (+0.28%) 04/28/20 Merck cuts FY20 EPS view to $5.17-$5.37 from $5.62-$5.77, consensus $5.56 04/28/20 Merck reports Q1 EPS $1.50, consensus $1.34 04/27/20 Notable companies reporting before tomorrow's open 04/27/20 Fly Intel: What to watch in Merck earnings report KURA Kura Oncology $17.10 / +0.39 (+2.33%) 05/04/20 Kura Oncology reports Q1 EPS (42c), consensus (42c) 02/25/20 Kura Oncology reports Q4 EPS (39c), consensus (41c) KPTI Karyopharm $18.80 / + (+0.00%) 05/05/20 Karyopharm reports Q1 EPS (78c), consensus (69c) 02/13/20 Karyopharm reports Q4 EPS (76c), consensus (67c) 01/13/20 Karyopharm sees FY19 XPOVIO product sales $30M-$31M 01/13/20 Karyopharm sees Q4 XPOVIO product sales $17M-$18M HALO Halozyme $23.49 / +0.02 (+0.09%) 05/11/20 Halozyme backs FY20 GAAP EPS view of 60c-75c, consensus 62c 05/11/20 Halozyme reports Q1 EPS (4c), consensus (2c) 02/24/20 Halozyme backs FY20 GAAP EPS view 60c-75, consensus 58c 02/24/20 Halozyme reports Q4 EPS (24c), consensus (15c) EXEL Exelixis $24.46 / +0.13 (+0.53%) 05/05/20 Exelixis sees FY20 revenue $850M-$900M, consensus $886.93M. 05/05/20 Exelixis reports Q1 adjusted EPS 19c, consensus 13c 02/25/20 Exelixis reports Q4 EPS 26c, consensus 16c 01/12/20 Exelixis sees FY20 revenue $850M-$900M, consensus $1B DCPH Deciphera $56.95 / +0.01 (+0.02%) 05/05/20 Deciphera reports Q1 EPS ($1.36), consensus ($1.25) 03/09/20 Deciphera reports Q4 EPS ($1.31), consensus ($1.18) CGEN Compugen $12.92 / +0.55 (+4.45%) 05/06/20 Compugen reports Q1 EPS (10c), consensus (10c) 02/20/20 Compugen reports Q4 EPS (10c), consensus (11c) BPMC Blueprint Medicines $66.44 / -0.56 (-0.84%) 05/06/20 Blueprint Medicines reports Q1 EPS ($2.11), consensus ($2.17) 02/13/20 Blueprint Medicines reports Q4 EPS ($1.35), consensus ($1.69) BMY Bristol-Myers $60.18 / +0.38 (+0.64%) 05/07/20 Bristol-Myers sees FY20 revenue $40B-$42B, consensus $41.65B 05/07/20 Bristol-Myers affirms FY21 adjusted EPS view $7.15-$7.45, consensus $7.38 05/07/20 Bristol-Myers affirms FY20 adjusted EPS view $6.00-$5.20, consensus $6.17 05/07/20 Bristol-Myers reports Q1 adjusted EPS $1.72, consensus $1.49 BLUE Bluebird Bio $61.30 / +0.49 (+0.81%) 05/11/20 Bluebird Bio reports Q1 EPS ($3.64), consensus ($4.01) 02/18/20 Bluebird Bio reports Q4 EPS ($4.04), consensus ($3.79) BCYC Bicycle Therapeutics $18.28 / + (+0.00%) 05/07/20 Bicycle Therapeutics reports Q1 EPS (63c), consensus 11c 03/10/20 Bicycle Therapeutics reports Q4 EPS (25c), consensus (52c) AZN AstraZeneca $54.97 / +1.47 (+2.75%) 02/14/20 AstraZeneca sees FY20 core EPS to increase by mid- to high-teens percentage 02/14/20 AstraZeneca reports Q4 core EPS 89c, consensus 98c 01/08/20 Veracyte announces biopharmaceutical collaboration with Acerta Pharma AVEO Aveo Pharmaceuticals $8.01 / -1.21 (-13.12%) 04/30/20 Aveo Pharmaceuticals reports Q1 EPS (52c), consensus (50c) 03/16/20 Aveo Pharmaceuticals reports Q4 EPS (28c), consensus (59c) ATNX Athenex $11.08 / -0.04 (-0.36%) 05/07/20 Athenex reports Q1 EPS (24c), consensus (17c) 02/27/20 Athenex reports Q4 EPS (28c), consensus (31c) AMGN Amgen $224.10 / +0.08 (+0.04%) 04/30/20 Amgen backs FY20 adjusted EPS view $14.85-$15.60, consensus $15.42 04/30/20 Amgen reports Q1 adjusted EPS $4.17, consensus $3.76 04/30/20 Notable companies reporting after market close 04/29/20 Fly Intel: What to watch in large-cap biotech earnings reports ALLO Allogene Therapeutics $45.80 / -0.8 (-1.72%) 05/06/20 Allogene Therapeutics reports Q1 EPS (50c), consensus (58c) 02/27/20 Allogene Therapeutics reports Q4 EPS (58c), consensus (68c) ABBV AbbVie $90.97 / +0.96 (+1.07%) 05/01/20 AbbVie sees Q2 adjusted EPS $2.10-$2.16, consensus $2.25 05/01/20 AbbVie backs FY20 adjusted EPS view $9.61-$9.71, consensus $9.48 05/01/20 AbbVie reports Q1 adjusted EPS $2.42, consensus $2.25 04/30/20 Notable companies reporting before tomorrow's open 29 May TRIL PFE MRK BMY AZN AMGN ABBV TRIL Trillium Therapeutics $6.20 / +0.435 (+7.55%) 03/11/20 Trillium could be 'compelling' target after Forty Seven deal, Dealreporter says PFE Pfizer $38.06 / -0.11 (-0.29%) 05/17/20 Coronavirus vaccine front-runners emerge, WSJ says 05/16/20 Too early to pick winners, losers in COVID-19 vaccine race, Barron's says 05/10/20 Pfizer to outsource some drug production, focus on COVID vaccine, Reuters says 05/05/20 ICE partners with Amazon, 3M to identify counterfeit coronavirus gear, WSJ says MRK Merck $79.24 / +0.22 (+0.28%) 05/26/20 Merck CEO: 12-18 month COVID vaccine timeline 'very aggressive,' FT reports 05/22/20 U.S. plans 'massive' vaccine testing with over 100,000 patients, Reuters says BMY Bristol-Myers $60.18 / +0.38 (+0.64%) 02/01/20 Oracle, Discovery still looking cheap, Barron's says 01/03/20 Novartis, Merck, Allergan raise U.S. prices on over 100 drugs, Reuters reports 12/13/19 Bristol-Myers awarded $585M in damages in patent win over Gilead, Bloomberg says 12/13/19 Bristol-Myers awarded $585M in damages in patent win over Gilead, Bloomberg says AZN AstraZeneca $54.97 / +1.47 (+2.75%) 05/29/20 AstraZeneca may consider exposing trial participants to virus, Reuters reports 05/27/20 AstraZeneca tests Farxiga as COVID-19 treatment, Reuters reports 05/22/20 U.S. plans 'massive' vaccine testing with over 100,000 patients, Reuters says 05/22/20 Astra-Oxford vaccine may be tested 'side-by-side' with Moderna's, Reuters says AMGN Amgen $224.10 / +0.08 (+0.04%) 05/28/20 Elliott says Alexion settlement may 'leave the door open' for strategic review 03/06/20 Roche bid to block Amgen's Herceptin biosimilar fails, Bloomberg reports 01/07/20 Amgen wins ruling that Amneal's Zydus infringes Sensipar patent, Bloomberg says ABBV AbbVie $90.97 / +0.96 (+1.07%) 03/23/20 AbbVie gives up patent rights for Keltra antiviral treatment, FT reports 03/19/20 AbbVie's Kaletra fails as treatment for severe COVID-19, Reuters reports 03/07/20 J&J, Amgen among healthy dividend stocks as COVID-19 fears grow, Barron's says 03/07/20 AT&T, Dow among dividend stocks to buy amid coronavirus selloff, Barron's says XNCR STML SGEN SBPH PFE MRSN MRK KPTI HALO EXEL DCPH BPMC BMY BLUE BCYC AZN AVEO ATNX AMGN ALLO ABBV XNCR Xencor $30.45 / -0.54 (-1.74%) 05/07/20 Fly Intel: After-Hours Movers STML Stemline $11.88 / -0.01 (-0.08%) 05/04/20 Fly Intel: Wall Street's top stories for Monday 05/04/20 Fly Intel: Wall Street's top stories at midday 05/04/20 Fly Intel: Pre-market Movers SGEN Seattle Genetics $154.34 / +2.57 (+1.69%) 05/01/20 Fly Intel: Gilead, Beyond Meat downgrades among today's top calls on Wall Street 04/30/20 Fly Intel: After-Hours Movers SBPH Spring Bank Pharmaceuticals $1.56 / -0.085 (-5.17%) 12/30/19 Bullish takes on Chipotle, Crowdstrike among today's top Wall Street calls 12/27/19 Downgrades of Spring Bank, Darden among today's top analyst calls 12/26/19 Fly Intel: Wall Street's top stories for Thursday 12/26/19 Fly Intel: Wall Street's top stories at midday PFE Pfizer $38.06 / -0.11 (-0.29%) 05/15/20 Fly Intel: Wall Street's top stories for Friday 05/15/20 Sarepta jumps after Pfizer announces DMD gene therapy data 05/05/20 Fly Intel: Wall Street's top stories for Tuesday 05/05/20 Fly Intel: Wall Street's top stories at midday MRSN Mersana Therapeutics $20.50 / +0.8 (+4.06%) 05/27/20 Fly Intel: Wall Street's top stories for Wednesday 04/13/20 Fly Insider: Carnival, SBA among week's notable insider transactions MRK Merck $79.24 / +0.22 (+0.28%) 05/26/20 Fly Intel: Wall Street's top stories for Tuesday 05/26/20 Fly Intel: Wall Street's top stories at midday 05/26/20 Fly Intel: Pre-market Movers KPTI Karyopharm $18.80 / + (+0.00%) 05/28/20 Fly Intel: After-Hours Movers 05/05/20 Fly Intel: Pre-market Movers 03/03/20 Fly Intel: Pre-market Movers HALO Halozyme $23.49 / +0.02 (+0.09%) 05/11/20 Fly Intel: After-Hours Movers EXEL Exelixis $24.46 / +0.13 (+0.53%) 04/20/20 Fly Intel: Wall Street's top stories for Monday 04/20/20 Fly Intel: Wall Street's top stories at midday 04/20/20 Fly Intel: Pre-market Movers DCPH Deciphera $56.95 / +0.01 (+0.02%) 03/12/20 Before the Move: Watch Blueprint Medicines into Phase 2 trial update BPMC Blueprint Medicines $66.44 / -0.56 (-0.84%) 04/28/20 Fly Intel: Wall Street's top stories for Tuesday 04/28/20 Fly Intel: Wall Street's top stories at midday 04/28/20 Fly Intel: Pre-market Movers BMY Bristol-Myers $60.18 / +0.38 (+0.64%) 05/26/20 Fly Intel: After-Hours Movers 05/07/20 Fly Intel: Pre-market Movers 05/06/20 Novo Nordisk slips as analysts discuss NASH data, read-through to peers BLUE Bluebird Bio $61.30 / +0.49 (+0.81%) 05/18/20 Fly Intel: Pre-market Movers 05/13/20 Fly Intel: Pre-market Movers BCYC Bicycle Therapeutics $18.28 / + (+0.00%) 03/10/20 Fly Intel: Pre-market Movers AZN AstraZeneca $54.97 / +1.47 (+2.75%) 05/23/20 Week in Review: How Trump's policies moved stocks 03/24/20 Innate rises again on potential use of cancer drug against COVID-19 03/02/20 Larger coronavirus drag on U.S. growth seen as analysts discuss further impact 01/13/20 Amarin jumps after AstraZeneca fish oil drug trial fails AVEO Aveo Pharmaceuticals $8.01 / -1.21 (-13.12%) 05/29/20 Fly Intel: Pre-market Movers 03/31/20 Fly Intel: After-Hours Movers ATNX Athenex $11.08 / -0.04 (-0.36%) 12/30/19 Fly Insider: Kodak, Quotient among week's notable insider trades 12/13/19 Fly Intel: Wall Street's top stories for Friday 12/13/19 Fly Intel: Wall Street's top stories at midday AMGN Amgen $224.10 / +0.08 (+0.04%) 05/28/20 Alexion rises as documents suggest settlement of Amgen patent challenge 05/28/20 Fly Intel: Pre-market Movers 03/30/20 Fly Intel: Alphabet upgrade among today's top calls on Wall Street 03/12/20 Piper sees trial disruption risk, calls out Moderna, Inovio as 'COVID-19 plays' ALLO Allogene Therapeutics $45.80 / -0.8 (-1.72%) 05/14/20 Fly Intel: Wall Street's top stories for Thursday 05/14/20 Allogene jumps, Compugen plunges following release of cancer meeting abstracts 05/14/20 Fly Intel: Pre-market Movers 05/13/20 Fly Intel: After-Hours Movers ABBV AbbVie $90.97 / +0.96 (+1.07%) 05/12/20 CarMax upgrade, Chevron downgrade among today's top calls on Wall Street 03/20/20 Inovio, Moderna gain ahead of Sunday's 60 Minutes report on COVID-19 vaccines 03/18/20 COVID-19 drug seen as possible this year, vaccine in 2021 as crisis continues 02/07/20 Fly Intel: Wall Street's top stories for Friday 05/29/20 Virtual Annual Meeting of ASCO 2020 05/29/20 Karyopharm - KPTI 05/29/20 Amgen - AMGN 07/31/20 Merck - MRK 06/04/20 PDUFA Date for RECARBRIO 06/16/20 PDUFA Date for KEYTRUDA 06/23/20 PDUFA Date for Oral XPOVIO (Selinexor) Tablets 08/06/20 PDUFA Date for CM-9LA Opdivo + Yervoy 08/13/20 PDUFA Date for Ripretinib 08/17/20 PDUFA Date for Lisocabtagene Maraleucel (liso-cel) 08/20/20 PDUFA Date for Tucantinib 09/03/20 PDUFA Date for CC-486 11/15/20 PDUFA Date 12/30/20 PDUFA Date for Tirbanibulin Ointment 05/29/20 Allogene Therapeutics 06/01/20 Compugen 06/05/20 Athenex, Inc. 06/05/20 Allogene Therapeutics, Inc. 06/10/20 Deciphera Pharmaceuticals, Inc. 06/10/20 AVEO Pharmaceuticals, Inc. 06/11/20 NextCure, Inc. 06/11/20 Syros Pharmaceuticals, Inc. 06/12/20 Mersana Therapeutics, Inc. 06/18/20 bluebird bio, Inc. 06/23/20 Blueprint Medicines Corp. 06/24/20 Spring Bank Pharmaceuticals, Inc. 06/24/20 Kura Oncology, Inc. 06/25/20 Xencor, Inc. TRIL RECN PFE MRSN MRK EXEL BMY AZN ABBV TRIL Trillium Therapeutics $6.20 / +0.435 (+7.55%) 05/05/20 Largest borrow rate increases among liquid names 04/03/20 Largest borrow rate increases among liquid names 02/11/20 Largest borrow rate increases among liquid names 02/05/20 Largest borrow rate increases among liquid names RECN Changed to RGP $0.00 / + (+0.00%) 04/02/20 Three new option listings and four option delistings on April 2nd PFE Pfizer $38.06 / -0.11 (-0.29%) 05/05/20 Unusually active option classes on open May 5th 04/28/20 Unusually active option classes on open April 28th 04/06/20 Unusual call flow in option market yesterday 04/03/20 Opening call sale in Pfizer struck 7.4% above spot MRSN Mersana Therapeutics $20.50 / +0.8 (+4.06%) 02/12/20 Four new option listings and one option delisting on February 12th MRK Merck $79.24 / +0.22 (+0.28%) 05/14/20 Early notable gainers among liquid option names on May 14th 04/09/20 Merck call volume above normal and directionally bullish 02/05/20 Unusually active option classes on open February 5th EXEL Exelixis $24.46 / +0.13 (+0.53%) 05/11/20 Exelixis call volume above normal and directionally bullish 05/08/20 Exelixis call volume above normal and directionally bullish 03/06/20 Exelixis call volume above normal and directionally bullish 02/18/20 Exelixis put volume heavy and directionally bearish BMY Bristol-Myers $60.18 / +0.38 (+0.64%) 05/01/20 Bristol Myers Squibb put volume heavy and directionally bearish 04/20/20 Bristol Myers Squibb call volume above normal and directionally bullish 04/20/20 Early notable gainers among liquid option names on April 20th 03/30/20 Unusually active option classes on open March 30th AZN AstraZeneca $54.97 / +1.47 (+2.75%) 05/28/20 Unusually active option classes on open May 28th 05/27/20 AstraZeneca call volume above normal and directionally bullish 05/22/20 Unusually active option classes on open May 22nd ABBV AbbVie $90.97 / +0.96 (+1.07%) 05/19/20 Unusually active option classes on open May 19th 05/12/20 Early notable gainers among liquid option names on May 12th 05/12/20 Unusually active option classes on open May 12th 02/07/20 Early notable gainers among liquid option names on February 7th
Syndicate	Mersana Therapeutics 8M share Secondary priced at $19.00 » 23:36 05/28/20 05/28 23:36 05/28/20 23:36 MRSN Mersana Therapeutics $19.70 / +1.52 (+8.36%) The deal size was… The deal size was increased to 8M shares of common stock from 5M shares of common stock. Cowen and SVB Leerink acted as joint book running managers for the offering. ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options MRSN Mersana Therapeutics $19.70 / +1.52 (+8.36%) 05/27/20 Mersana Therapeutics reports interim Phase 1 data for XMT-1536 cancer candidate 05/14/20 Mersana Therapeutics initiates patient dosing in XMT-1592 dose escalation study 05/13/20 Mersana Therapeutics to report interim data from Phase 1 dose expansion of XMT-1 04/15/20 Mersana Therapeutics appoints Martin Huber to board of directors MRSN Mersana Therapeutics $19.70 / +1.52 (+8.36%) 05/27/20 H.C. Wainwright Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright 04/29/20 BTIG Mersana Therapeutics initiated with a Buy at BTIG 01/21/20 H.C. Wainwright Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright 08/20/19 H.C. Wainwright H.C. Wainwright says trial initiation at higher dosing 'bodes well' for Mersana MRSN Mersana Therapeutics $19.70 / +1.52 (+8.36%) 05/08/20 Mersana Therapeutics reports Q1 EPS (35c), consensus (37c) 02/28/20 Mersana Therapeutics reports Q4 EPS (34c), consensus (38c) 29 May MRSN Mersana Therapeutics $19.70 / +1.52 (+8.36%) 05/27/20 Fly Intel: Wall Street's top stories for Wednesday 04/13/20 Fly Insider: Carnival, SBA among week's notable insider transactions 05/29/20 Virtual Annual Meeting of ASCO 2020 06/12/20 Mersana Therapeutics, Inc. MRSN Mersana Therapeutics $19.70 / +1.52 (+8.36%) 02/12/20 Four new option listings and one option delisting on February 12th

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial